WO2004060425A2 - Compositions and methods of using collagen and mmpi - Google Patents

Compositions and methods of using collagen and mmpi Download PDF

Info

Publication number
WO2004060425A2
WO2004060425A2 PCT/US2003/041330 US0341330W WO2004060425A2 WO 2004060425 A2 WO2004060425 A2 WO 2004060425A2 US 0341330 W US0341330 W US 0341330W WO 2004060425 A2 WO2004060425 A2 WO 2004060425A2
Authority
WO
WIPO (PCT)
Prior art keywords
mmpi
collagen
implant
composition
timp
Prior art date
Application number
PCT/US2003/041330
Other languages
English (en)
French (fr)
Other versions
WO2004060425A3 (en
Inventor
William L. Hunter
David M. Gravett
Philip M. Toleikis
Arpita Maiti
Original Assignee
Angiotech International Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiotech International Ag filed Critical Angiotech International Ag
Priority to AU2003300379A priority Critical patent/AU2003300379A1/en
Priority to CA002509060A priority patent/CA2509060A1/en
Priority to JP2004565732A priority patent/JP2006516252A/ja
Priority to BR0317715-7A priority patent/BR0317715A/pt
Priority to EP03814968A priority patent/EP1585555A2/en
Publication of WO2004060425A2 publication Critical patent/WO2004060425A2/en
Publication of WO2004060425A3 publication Critical patent/WO2004060425A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/10—Hair or skin implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/60—Materials for use in artificial skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/043—Proteins; Polypeptides; Degradation products thereof
    • A61L31/044—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/30—Joints
    • A61F2/44—Joints for the spine, e.g. vertebrae, spinal discs
    • A61F2/4455—Joints for the spine, e.g. vertebrae, spinal discs for the fusion of spinal bodies, e.g. intervertebral fusion of adjacent spinal bodies, e.g. fusion cages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/28—Bones
    • A61F2002/2817—Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes

Definitions

  • the present invention relates generally to pharmaceutical compositions, devices and methods, and more specifically, to compositions, devices and methods related to enhancing the duration and activity of implanted collagen materials.
  • Collagen is one of the most abundant proteins in mammals, representing up to 30% of the dry weight of the human body (see, L. C. Junqueira and J. Carneiro, Basic Histology, 4th ed., Lange Medical Publications, Los Altos, Calif, 1983, pp. 89- 119). Collagen provides strength and flexibility for skin, hair and nails, and is also a major and essential component of muscles, tendons, cartilage, ligaments, joints and blood vessels.
  • Collagen can be found in at least five different naturally occurring forms that are produced by several different cell types.
  • Type I collagen is the most abundant form of collagen, and can be found throughout the body. It is produced by fibroblasts, osteoblasts, odontoblasts, and chondroblasts, and can be found in bones, dentin, dermis, and fibrous cartilage.
  • Type II collagen is produced by chondroblasts, and can be found primarily in cartilage.
  • Type III collagen is produced by smooth muscle fibroblasts, reticular cells, Schwann cells, and hepatocytes. Its primary function is to maintain the structure of organs, and can be found in smooth muscles, endoneuriurn, arteries, uterus, liver, spleen, kidney, and lung tissue.
  • Type IV collagen is primarily believed to be involved in support and filtration, and can be found in the epithelial and endothelial basal lamina and basement membranes.
  • Type V collagen is found in fetal membranes, blood vessels, and placental basement membrane.
  • Collagen has been suggested for use in the treatment of a variety of medical applications, including for example, cosmetic surgery, arthritis, skin regeneration, implants, organ replacement, and treatment for wounds and burns (see e.g., U.S. Pat. Nos. 6,309,670, 5,925,736, 5,856,446, 5,843,445, 5,800,811, 5,783,188, 5,720,955, 5,383,930, 5,106,949, 5,104,660, 5,081,106, 4,837,379, 4,604,346, 4,485,097, 4,546,500, 4,539,716, and 4,409,332) and provides an attractive alternative to the use of injectable botulinum toxin drugs, such BOTOX (Allergan, Inc., Irvine, CA).
  • BOTOX Allergan, Inc., Irvine, CA.
  • Collagen however, has presented several problems associated with medical applications. For example, in the context of implants ⁇ collagen preparations with impurities are potent im unogens that can stimulate an inflammatory response. Similarly, non-human forms of collagen such as bovine collagen have been associated with a chronic cellular inflammatory reaction that can result in scar tissue and adhesion formation, and transient low-grade fevers. In addition, the duration of implantable collagen is limited, requiring procedures (especially for cosmetic enhancement) to be repeated on a regular basis.
  • the present invention addresses shortcomings associated with collagen and the use thereof in medical applications.
  • the present invention provides compositions, devices, and methods for prolonging the activity of collagen-based implants.
  • Collagen-based implants are used to provide structure and support in a variety of medical procedures including dermal injections for cosmetic purposes (to reduce wrinkles, scars, contour defects), periurethral bulking agents for the management of incontinence, and vascular "plugs" to produce hemostasis following vascular puncture procedures.
  • dermal injections for cosmetic purposes (to reduce wrinkles, scars, contour defects), periurethral bulking agents for the management of incontinence, and vascular "plugs" to produce hemostasis following vascular puncture procedures.
  • collagen implants While extremely effective, collagen implants have a short duration of activity in vivo since the material is rapidly broken down by degradative enzymes (principally collagenase and other matrix metalloprotemase enzymes) released by white blood cells and connective tissue cells (fibroblasts) adjacent to the implant. The result is that the collagen implant procedure must be repeated at frequent intervals to maintain the desired affect.
  • the present invention describes compositions that combine collagen and a compound that inhibits the activity of collagenase to produce a collagen-based implant with enlianced durability in vivo ("CoUajolie”).
  • a variety of naturally occurring and synthetically created molecules are known to inhibit collagenase activity, and have been used for purposes other than that of the present invention (e.g., the treatment of malignancy, arthritis and other disorders) where these inhibitors are collectively known as “matrix metalloprotemase inhibitors” (abbreviated as MMP inhibitors, or MMPIs) or “collagenase inhibitors”.
  • MMP-1 collagenase I, fibroblast collagenase; EC 3.4.24.3
  • MMP-2 gelatinase A, 72 kDa gelatinase, basement membrane collagenase, EC 3.4.24.24)
  • MMP-3 stromelysin 1, EC 3.4.24.17
  • MMP-7 proteoglycanase, matrilysin
  • MMP-8 collagenase II, neutrophil collagenase, EC 3.4.24.34
  • MMP-9 gelatinase B, 92 kDa gelatinase, EC 3.4.24.35
  • MMP-10 stromelysin 2, EC 3.4.24.22
  • MMP-11 stromelysin 3
  • MMP-12 metaloelastase, HME, human macrophage elastase
  • MMP- 13 collagenase III
  • MMP- 14 methyl- 14
  • the present invention is directed to inhibiting MMPs that degrade collagen.
  • MMPI suitable for use within the present invention include TIMP-1, tetracycline, doxycycline, minocycline, BATIMASTAT, MARIMASTAT, RO-1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE.
  • the compositions described herein may also further comprise one or more factors, compounds or agents which encourage or enhance bone growth, including for example, hydroxyapatite and bone morphogenic proteins (BMP, e.g., BMP-2).
  • BMP bone morphogenic proteins
  • compositions comprising collagen and a matrix metalloprotease inhibitor (MMPI).
  • MMPI matrix metalloprotease inhibitor
  • the compositions may further include hydroxyapatite.
  • the MMPI is a Tissue Inhibitor of Matrix Metalloprotemase (e.g., TIMP- 1, TIMP-2, TIMP-3, or, TIMP-4).
  • the MMPI is tetracycline, or an analog or derivative thereof (e.g., minocycline, or, doxycline); a hydroxamate (e.g., BATIMISTAT, MARIMISTAT, or, TROCADE); RO-1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, or SU-5402.
  • a hydroxamate e.g., BATIMISTAT, MARIMISTAT, or, TROCADE
  • the MMPI may be a polypeptide inhibitor (e.g., an inhibitor of a metalloprotease maturase), a mercapto- based compound, or a bisphosphonate with structure (I): wherein R' and R" are independently a hydrogen, a halogen, a hydroxy, an amino group or a substituted derivative thereof, a tliio group or a substituted derivative thereof, or an alkyl, alkanyl, alkenyl, alkynyl, alkyldiyl, alkyleno, heteroalkyl, heteroalkanyl, heteroalkenyl, heteroalkanyl, heteroalkyldiyl, heteroalkyleno, aryl, arylalkyl, heteroaryl, or heteroarylalkyl group, or a substituted derivative thereof.
  • R' and R" are independently a hydrogen, a halogen, a hydroxy, an amino group or a substituted derivative thereof, a t
  • R" are independently hydroxy, hydrogen, or chlorine.
  • the invention provides a composition that includes collagen, hydroxyapatite, and at least two MMPIs.
  • the composition may include a tetracycline, or an analog or derivative thereof and a bisphosphonate.
  • the composition includes a tetracycline, or an analog or derivative thereof and a hydroxymate.
  • the instant compositions may include collagen, at least one MMPI, and at least one polymer.
  • the polymer is a biodegradable polymer (e.g., albumin, gelatin, starch, cellulose, dextrans, polysaccharides, fibrinogen, poly (esters), poly (D,L lactide), poly (D,L-lactide-co- glycolide), poly (glycolide), poly( ⁇ -caprolactone), poly (hydroxybutyrate), poly
  • a biodegradable polymer e.g., albumin, gelatin, starch, cellulose, dextrans, polysaccharides, fibrinogen, poly (esters), poly (D,L lactide), poly (D,L-lactide-co- glycolide), poly (glycolide), poly( ⁇ -caprolactone), poly (hydroxybutyrate), poly
  • a non-biodegradable polymer e.g., an ethylene oxide and propylene oxide copolymer, an ethylene vinyl acetate copolymer, silicone rubber, a poly (methacrylate) based polymer, or a poly (acrylate) based polymer.
  • the collagen is a type I collagen or is a type II collagen.
  • the compositions provided herein may contain other compounds or compositions, including for example, thrombin and or dyes, or a bone morphogenic protein, such as BMP-2 or BMP-8.
  • the composition may be sterile, and the compositions may be sterilized in a manner suitable for human administration.
  • compositions described herein may be utilized for a variety of indications, including for example, as a medical device to augment bone growth, in spinal fusion surgery, as a surgical sling, mesh, or patch, for the treatment of periodontal disease (e.g., as a dental implant), as a skin graft (e.g., for the development of artificial skin), as a corneal shield, or as a glaucoma drainage device.
  • the medical device may be a collagen sponge that includes an MMPI (for representative discussions of collagen sponges, see, e.g., U.S.
  • the device may further include a polymer, as described above.
  • compositions described herein comprising the step of mixing a collagen and one or more MMPI as described herein, preferably in combination with one or more factors, agents or compounds which encourage or assist bone growth including, for example, hydroxyapatite and bone morphogenic proteins (BMP, e.g., BMP-2 and BMP-8).
  • BMP bone morphogenic proteins
  • the compositions and devices provided herein may be sterilized.
  • a method for surgically fusing a portion of a spine including removing a portion of a degenerated disc from the spine of a patient to form a disc space, and inserting into the disc space a medical device (either with or without hydroxyapatite) such as described herein.
  • the device may include, e.g., 0.001% to 15% of the MMPI by weight.
  • a method for augmenting bone or replacing lost bone is described. The method includes delivering to a patient in need thereof at a desired location a composition including collagen, an MMPI, and hydroxyapatite.
  • the invention provides a method of treating periodontal disease comprising placing a dental implant that includes collagen and a MMPI (either_with or without hydroxyapatite) between gingival tissue and a debrided periodontal defect in the mouth of a patient in need thereof.
  • a dental implant that includes collagen and a MMPI (either_with or without hydroxyapatite) between gingival tissue and a debrided periodontal defect in the mouth of a patient in need thereof.
  • compositions including collagen and an MMPI may be treated with the use of compositions including collagen and an MMPI according to the present invention.
  • a method of treating gastroesophageal reflux disease is described that includes injecting the composition in accordance with the invention into the vicinity of the lower esophageal sphincter of a patient.
  • a method of treating fecal incontinence is described that includes injecting the composition into the vicinity of the anal sphincter of a patient.
  • the instant invention provides a method of reinforcing soft tissue during an operative repair (e.g., an abdominal or thoracic wall repair, a hernia repair, a suture line reinforcement, an ostomy reinforcement, a tissue flap donor site repair, or a repair of a tendon, ligament, or cartilage) comprising attaching to the soft tissue a surgical patch that includes collagen and an MMPI (see, e.g., U.S. Patents 6,238,416; 5,665,114; and 5,290,217 for representative discussions of surgical patches).
  • an operative repair e.g., an abdominal or thoracic wall repair, a hernia repair, a suture line reinforcement, an ostomy reinforcement, a tissue flap donor site repair, or a repair of a tendon, ligament, or cartilage
  • the invention provides a method of improving drainage of the aqueous humor following a sclerectomy comprising inserting into a subscleral drainage channel a glaucoma drainage device that includes collagen and an MMPI.
  • a method of improving wound healing includes applying a wound dressing that includes collagen and an MMPI to a wound surface.
  • the present invention describes a method of improving post-operative healing of cornea following cataract surgery comprising applying a corneal shield that includes collagen and an MMPI to scleral or conjunctival tissue.
  • Collagen refers to all forms of collagen as are described or referenced herein, including those that have been processed or modified. Representative examples include type I and type II collagen. Collagen may be prepared from human or animal sources, or, may be produced using recombinant techniques. "Matrix Metalloprotemase Inhibitor” or “MMPI” refers to a compound, agent or composition that inhibits matrix metalloprotemase activity.
  • MMP Inhibitors include Tissue Inhibitors of Metalloproteinases (TIMPs) (e.g., TIMP-1, TIMP-2, TIMP-3, or TIMP-4), ⁇ 2 -macroglobulin, tetracyclines (e.g., tetracycline, minocycline, and doxycycline), hydroxamates (e.g., BATIMASTAT, MARIMISTAT and TROCADE), chelators (e.g., EDTA, cysteine, acetylcysteine, D- penicillamine, and gold salts), synthetic MMP fragments, succinyl mercaptopurines, phosphonamidates, and hydroxaminic acids.
  • TIMPs Tissue Inhibitors of Metalloproteinases
  • TIMP-4 TIMP-1, TIMP-2, TIMP-3, or TIMP-4
  • ⁇ 2 -macroglobulin e.g., tetracyclines (e.g.,
  • Collagen is the major component in skin, cartilage, bone, and connective tissue, and occurs in several different types or forms, with Types I, II, III, and IV being most common.
  • Collagen typically is isolated from natural sources, such as bovine bone, cartilage, or hide. Bones are usually defatted, crushed, dried, and demineralized to extract the collagen. In contrast, bovine cartilage or hide is usually minced and digested with enzymes other than collagenase (in order to remove contaminating protein).
  • Collagen can also be prepared from human tissue (the patient's own or donor tissue) or by recombinant methods.
  • preferred collagens are prepared as non-immunoreactive sterile compositions. They may be soluble (e.g., VITROGEN collagen in solution, available from Cohesion Technologies, Palo Alto, CA), or be in the form of reconstituted fibrillar atelopeptide collagen, for example ZYDERM Collagen Implant available from Inamed Aesthetics, Santa Barbara, CA).
  • VITROGEN collagen in solution available from Cohesion Technologies, Palo Alto, CA
  • ZYDERM Collagen Implant available from Inamed Aesthetics, Santa Barbara, CA.
  • collagens include tissue engineered human collagen products designed for wrinkle reduction, such as COSMODERM, which is intended to treat surface areas, and COSMOPLAST (both from Inamed Aesthetics), which is for treating larger voids, and viscoelastic injectable gel formulations, such as HYLAFORM (Inamed Aesthetics), for the same-day treatment of facial wrinkles and scars.
  • COSMODERM tissue engineered human collagen products designed for wrinkle reduction
  • COSMOPLAST both from Inamed Aesthetics
  • HYLAFORM Inamed Aesthetics
  • MMPs Metalloproteinases
  • Metalloproteinases are a group of naturally occurring zinc-dependent enzymes involved in the breakdown and turnover of extracellular matrix macromolecules. Over 23 metalloproteinases have been identified to date and have been broadly categorized into families of enzymes known as collagenases, stromelysins, gelatinases, elastases and matrilysins. Metalloproteinases are derived from a variety of cell types including neutrophils, monocytes, macrophages and fibroblasts. MMPs are the principle enzymes involved in the breakdown and normal turnover of collagen in vivo.
  • MMP-1, MMP-8, MMP- 13 and MMP- 14 the enzymes with the highest specificity for collagen come from the collagenase family (e.g., MMP-1, MMP-8, MMP- 13 and MMP- 14).
  • Metalloprotemase activity is inhibited naturally in vivo by a family of inhibitors known as "Tissue Inhibitors of Metalloprotemase” or "TIMPs” which bind to the active region of the metalloprotemase enzyme rendering it inactive. It is the natural balance between enzyme activity and inhibition that regulates the rate of metabolism of the extracellular matrix under physiologic conditions.
  • Assays for measuring MMP inhibition are readily known in the art, and include, for example, the following: Cawston T.E., Barrett A.J., "A rapid and reproducible assay for collagenase using [ 14 C] acetylated collagen," Anal. Biochem. 55:1961-1965 (1963); Cawston T.E., Murphy G, “Mammalian collagenases,” Methods in Enzymology 50:711 (1981); Koshy P.T.J., Rowan A.D., Life P.F., Cawston T.E., "96- well plate assays for measuring collagenase activity using (3)H-acetylated collagen," Anal. Biochem.
  • an MMPI may have an Inhibitory Concentration (IC) ranging from about 3-10 mM to about 9-10 nM, with preferred concentrations of about 50 mM to about 50 nM.
  • IC Inhibitory Concentration
  • the present invention describes incorporating into the collagen implant an agent or agents capable of inhibiting MMP activity so as to tip the physiologic balance in favor of collagen preservation.
  • This invention is compatible with, and can be used in combination with other preservation strategies, such as collagen crosslinking, designed to increase the residence time of a collagen implant.
  • MMPs pathologic production of MMPs has been associated with a variety of clinically important disease processes such as tumor metastasis and the progression of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis
  • numerous naturally occurring and synthetic agents have been developed to inhibit MMP activity.
  • regulation of MMP activity is an important and highly regulated process in vivo.
  • sites in the pathway leading to MMP production where it is possible to develop molecules capable of inhibiting MMP synthesis or activity.
  • the types of agents capable of inhibiting MMP activity are described in more detail below, and may be used according to the compositions, methods and devices of the present invention.
  • cytokines e.g., TNF- ⁇ , IL-1, FGF and others
  • Inhibitors of these cytokines or agents which block their cellular receptors have been demonstrated to inhibit MMP synthesis under certain circumstances and are suitable for use in this invention.
  • the stimulus for MMP production triggers the production of a variety of second messengers and cell signaling molecules (e.g., jun kinase, JKK), inhibition of which can also reduce the production of MMPs.
  • second messengers and cell signaling molecules e.g., jun kinase, JKK
  • transcription factors e.g., c-fos, c-jun, NF ⁇ -B, c-myc
  • Inhibitors of these transcription factors and their products can also decrease the amount of MMPs transcribed and can be utilized for the purposes of this invention.
  • strategies that inhibit the MMP gene itself e.g., gene knockout
  • MMP RNA e.g., antisense, ribozymes, tetracycline, doxycycline, minocycline
  • MMP RNA e.g., antisense, ribozymes, tetracycline, doxycycline, minocycline
  • MMPs are secreted from the cell as inactive precursor proteins (called Pro-MMPs) that are subsequently converted to the active enzyme through a highly specific enzymatic cleavage (catalyzed by enzymes such as plasmin, mast cell protease, cathepsin G, plasma kallikrein and others), it is possible to inhibit the conversion of the MMP from its inactive to active state (thereby maintaining it in an inactive form).
  • Inhibitors of the enzymes responsible for the conversion of the MMP from its inactive to active state can also be utilized for this invention.
  • an activated MMP through several mechanisms such as chelation of its zinc metal active center (e.g., EDTA, cysteine, acetylcysteine, D-penicillamine, gold salts; hydroxamates such as BATIMASTAT, MARIMASTAT, TROCADE (F.
  • chelation of its zinc metal active center e.g., EDTA, cysteine, acetylcysteine, D-penicillamine, gold salts
  • hydroxamates such as BATIMASTAT, MARIMASTAT, TROCADE (F.
  • TIMPs Tissue Inhibitors of Metalloproteinases
  • TIMP-1 TIMP-1
  • TIMP-2 TIMP-2
  • TIMP-3 TIMP-3
  • TIMP-4 Tissue Inhibitors of Metalloproteinases
  • Still other inhibitors act by preventing binding of the MMP to' its substrate (e.g., synthetic MMP fragments, synthetic collagen fragments) and may be utilized alone, or in combination with other MMPIs for the purpose of this invention. It should be clear to one of skill in the art that regardless of the specific mechanism of inhibition, any agent capable of inhibiting the production, activation or enzymatic function of the MMP enzymes are ideal agents for the purposes of this invention.
  • MMPIs include actinonin (3-[[l-[[2- (hydroxymethyl)-l-pyrolidmyl]carbamoyl]-octano-hydroxa ⁇ nic acid); bromocyclic- adenosine monophosphate; N-chlorotaurine; BATIMISTAT, also known as BB-94 (British Biotech, UK); CT1166, also known as Nl ⁇ N-[2-(morpholinosulphonylamino)- ethyl]-3-cyclohexyl-2-(S)-propanamidyl ⁇ -N4-hydroxy-2-(R)-[3-(4- methylphenyl)propyl]-succinamide (Biochem.
  • estramustine estradiol-3-bis(2-chloroethyl)carbamate
  • eicosa-pentaenoic acid MARIMASTAT (also known as BB-2516); matlystatin-B; peptidyl hydroxamic acids such as pNH 2 -Bz-Gly- Pro-D-Leu-D-Ala-NHOH (Biophys. Biochem. Res. Comm.
  • N- phosphonalkyl dipeptides such as N-[N-((R)-l-phosphonopropyl)-(S)-leucyl]-(S)- phenylalanine-N-methylamide (J. Med. Chem.
  • MMPIs include, for example, chelators (e.g., EDTA, cysteine, acetylcysteine, D-penicillamine, and gold salts); bis(dioxopiperzaine), see U.S. Pat. No. 5,866,570; NEOVASTAT (Les Laboratoires Aeterna, Inc., Canada), which inhibits gelatinolytic and elastinolytic activities for MMP-2, MMP-9, and MMP- 12 (see, e.g., U.S. Patent No.
  • Patent No. 5,837,696 ; DAC-MMPI (ConjuChem Inc., Canada); RS-1130830 and RS-113-080 (F. Hoffmann-La Roche Ltd., Switzerland); GM-1339 (Ligand Pharmaceuticals, Inc., San Diego, CA); GI-155704A (GlaxoSmithKline, UK); ONO-4817 (Ono Pharmaceutical Co., Osaka, Japan); AG- 3433, AG-3088, PRINOMASTAT (Agouron Pharmaceuticals, San Diego, CA; see, e.g., U.S. Patent No. 5,753,653), CP-544439 (Pfizer Inc., New York, NY; U.S. Patent No.
  • MMPIs are described, e.g., in U.S. Patent Nos. 4,235,885; 4,263,293; 4,276,284; 4,297,275; 4,367,233; 4,371,465; 4,371,466; 4,374,765; 4,382,081; 4,558,034; 4,704,383; 4,950,755; 5,270,447, 6,294,694, and 6,329,550.
  • MMPIs Tissue Inhibitors of Matrix Metalloproteinases (TIMPs); (2) tetracyclines, (3) hydroxamates, (4) synthetic MMP fragments (e.g., peptide inhibitors), (5) mercapto-based compounds, and (6) bisphosphonates.
  • Tissue Inhibitors of Matrix Metalloproteinases Tissue Inhibitors of Matrix Metalloproteinases (TIMPs); (2) tetracyclines, (3) hydroxamates, (4) synthetic MMP fragments (e.g., peptide inhibitors), (5) mercapto-based compounds, and (6) bisphosphonates.
  • Tissue Inhibitors of Matrix Metalloproteinases Tissue Inhibitors of Matrix Metalloproteinases (TIMPs); (2) tetracyclines, (3) hydroxamates, (4) synthetic MMP fragments (e.g., peptide inhibitors), (5) mercapto-based compounds, and (6) bisphosphonates.
  • Tissue Inhibitors of Matrix Metalloproteinases are classified based upon their ability to inhibit metalloproteinases, structural similarity to each other, the 12 cysteines which form disulfide bonds important in secondary structure, and the presence of a VIRAF motif which interacts with the metal ion of the metalloproteinases.
  • the nucleic acid and amino acid sequences of TIMPs have been described: TIMP-1 (Docherty, A. J. P. et al., (1985) Nature 318: 66-69), TIMP-2 (Boone, T. C, et al. (1990) Proc. Natl. Acad. Sci. 87: 2800-2804; Stetler-Stevenson, W.
  • TIMP-3 Tissue Inhibitor of Metalloproteinases
  • TIMP-3 Tissue Inhibitor of Metalloproteinases
  • TIMP-1 is a 30 kD protein, and is the most commonly expressed TIMP molecule. It contains two asparagine residues which act as carbohydrate binding sites, one in loop 1 and one in loop 2 (Murphy and Dockerty, supra). In addition, a truncated form of TIMP-1 which contains only the first three loops of the molecule is able to inhibit MMPs. Although TIMP-1 is a better inhibitor of interstitial collagenase than TIMP-2 (Howard, E. W, et al. (1991) J. Biol. Chem. 266: 13070-75), the 23 kD TIMP- 2 molecule is the most effective inhibitor of gelatinases A and B.
  • TIMP-3 is a 21 kD protein which inhibits collagenase 1, stromelysin, and gelatinases A and B (Apte, S.S., et al. (1995) J. Biol. Chem. 270: 14313-18) and may be induced by mitogens (Wick, et al. (1994) J Biol. Chem. 269: 18953-60).
  • any of the four TIMP molecules are capable of inhibiting the activity of virtually all of the MMPs identified to date and would be suitable for the purposes of this invention.
  • TIMP-1 which has a high specificity for the inhibition of collagenase, would be particularly preferred for incorporation into a collagen implant.
  • Tetracyclines are a class of analog and derivative compounds known originally for their use as antibiotics. Numerous tetracyclines, including tetracycline, doxycycline, minocycline and others, have been demonstrated to inhibit the production and activity of MMPs. Although the exact mechanism is incompletely understood, MMP inhibition may occur through downregulation of MMP expression and/or post- translationally through chelation of the zinc metal active site. Given their widespread use and low toxicity, these compounds would be of particular utility for incorporation into a collagen implant.
  • the parent compound of the tetracycline family, tetracycline has the following general structure:
  • the multiple ring nucleus can be numbered as follows:
  • Tetracycline as well as the 5 -OH (oxytetracycline) and 7-C1 (chlorotetracycline) derivatives exist in nature and are well known antibiotics.
  • Other tetracyclines include, for example, apicycline, chelocardin, clomocycline, demeclocycline, doxycycline, etamocycline, guamecycline, lymecycline, meglucyccline, mepycyhcline, minocycline, methacycline, penimepicycline, piacycline, rolitetracycline, and sancycline.
  • Tetracycylines can also be modified so that they retain their structural relationship to antibiotic tetracyclines, but have their antibiotic activity substantially or completely reduced by chemical modification.
  • Representative examples of chemically modified tetracyclines (CMT's) include, for example, CMT-1 (4-de(dimethylamino)- tetracycline), CMT-2 (tetracyclinonitrile), CMT-3 (6-demethyl-6-deoxy-4- de(dimethylamino)tetracycline), CMT-4 (7-chloro-4-de(dimethylamino)tetra-cycline), CMT-5 (tetracycline pyrazole), CMT-6 (4-hydroxy-4-de(dimethylamino)tetra-cycline), CMT-7 (4-de(dimethylamino)-12 ⁇ -deoxytetracycline), CMT-8 (6-deoxy-5 ⁇ -hydroxy-4- de(dimethylamino)tetracycline), CMT-9 (4-de(dimethyl
  • tetracyclines including tetracycline derivatives
  • hydroxamates A further class of compounds which inhibit MMPs are hydroxamates (or hydroxamic acids). Although the exact mechanism of MMP inhibition by hydroxamates is not precisely known, it is believed these compounds exert their effect primarily through interaction with the zinc metal active site in the enzyme (e.g., by coordinating with the catalytic zinc in a bidentate manner to adopt a triagonal bipyrimidal geometry).
  • hydroxamates have been synthesized and tested in several disease states with mixed clinical results. However, given their selective activity against MMPs and their excellent safety and tolerability, these agents would be particularly preferred for incorporation into a collagen implant to enhance the durability of the implant. Hydroxamates (or hydroxamic acids) have the general structures shown below:
  • A is HN(OH)-CO- or HCO-N(OH)-;
  • R 1 is C 2 -C 5 alkyl;
  • R 2 is the characterizing group of a natural ⁇ amino acid which may be protected provided that R is not H or methyl;
  • R 3 is H, NH 2 , OH, SH, C ⁇ -C 6 alkyl, d-C 6 alkoxy, d-C 6 alkylamino, -C 6 alkylthio, aryl (Ci-C ⁇ alkyl), or amino(C 1 -C 6 alkyl), hydroxy(C 1 -C 6 alkyl), mercapto(C!-C 6 alkyl) or carboxy ⁇ - alkyl) where the amino, hydroxy, mercapto or carboxyl group can be protected, the amino group may be acylated or the carboxyl group may be amidated;
  • R 4 is H or methyl;
  • R 5 is H, Q-C ⁇ alkyl, -C ⁇ al
  • R is - alkyl
  • R is -C ⁇ alkyl, benzyl, hydroxybenzyl, benzyloxybenzyl, (C C 6 alkoxy) benzyl or benzyloxy ( -C alkyl)
  • R 3 is hydrogen, d-C 6 alkyl, phenyl or phenyl (d-C 6 alkyl)
  • R 4 is H or d-C 6 alkyl, phenyl (d-C 6 alkyl), cycloalkyl or cycloalkyl (d-C 6 alkyl).
  • EP-A-0214639 see, e.g., EP-A-0214639.
  • R 1 is hydrogen or hydroxy
  • R 2 is hydrogen or alkyl
  • R 3 is C 3- C 6 alkyl
  • R 4 is hydrogen, alkyl, — CH Z where Z is optionally substituted phenyl or heteroaryl, or R 4 is a group C(HOR 8 )R 9 where R 8 is hydrogen, alkyl of CH 2 Ph where Ph is optionally substituted phenyl, and R 9 is hydrogen or alkyl
  • R 5 is hydrogen or alkyl.
  • R 1 is hydrogen, alkyl or optionally substituted aryl
  • R 2 is hydrogen or acyl such as CO alkyl or COZ where Z is optionally substituted aryl
  • R 3 is C 3-6 alkyl
  • R 4 is hydrogen, alkyl, — CH 2 R 10 where R 10 is optionally substituted phenyl or heteroaryl, or R 4 is a group C(HOR ⁇ )R 12 where R 11 is hydrogen, alkyl or CH Ph where Ph is optionally substituted phenyl, and R is hydrogen or alkyl
  • R is hydrogen, alkyl or a group C(HR 13 )COR 14 where R 13 is hydrogen, or alkyl, and R 14 is hydroxy, alkoxy, or — NR 6 R 7 , where each of R 6 or R 7 is hydrogen or alkyl, or R 6 and R 7 together with the nitrogen atom to which they are bonded form a 5-, 6 or 7 membered ring with optional oxygen or sulfur atom in the ring or an optional further
  • R 1 and R 2 are independently H, alkyl, alkoxy, halogen or CF 3 , R 3 is H, acyl, such as COalkyl or COZ, where Z is optionally substituted aryl, or a group RS where R is an organic residue such that the group RS provides an in vivo cleavable disulphide bond;
  • R 4 is C 3- C 6 alkyl,
  • R 5 is H, alkyl, — CH 2 R 10 where R 10 is optionally substituted phenyl or heteroaryl, or a group C(HOR u )R 12 where R 11 is hydrogen, alkyl or CH 2 Ph where Ph is optionally substituted phenyl, and R 12 is hydrogen or alkyl;
  • R 6 is hydrogen, alkyl or a group C(HR 13 )COR 14 where R 13 is hydrogen, or alkyl, and R 14 is hydroxy, alkoxy, or — NR 7 R 8 , where each of R 7 or R 8 is hydrogen or alky
  • R is hydrogen, d-C 6 alkyl or optionally substituted benzyl, R 1 is hydrogen or d.C ⁇ alkyl, R 2 is C -C 6 alkyl, R 3 is hydrogen, alkyl, — CH 2 Z where Z is optionally substituted phenyl or heteroaryl, or R 3 is a group C(HOR 7 )R 8 where R 7 is hydrogen, alkyl or CH 2 Ph where Ph is optionally substituted phenyl, and R 8 is hydrogen or alkyl; and R 4 is — CH 2 — (CH 2 ) classroomOR 5 , — CH 2 — (CH 2 ) favorOCOR 6 or — CH(R 9 )COR 10 , where n is an integer from 1 to 6; R 5 , R 6 and R 9 are hydrogen or d-C 6 alkyl; and R 10 is hydroxy or O(d-C 6 alkyl) or NR 5 R 6 where R 5 and R 6 may be linked to form a heterocyclic ring; or
  • R 1 is H, d-C 6 alkyl, phenyl, thienyl, substituted phenyl, phenyl (C ⁇ -C ⁇ )alkyl, heterocyclyl, (d-C 6 )alkylcarbonyl, phenacyl or substituted phenacyl group; or, when n is 0, R 1 represents SR*, wherein R* represents a group of the formula:
  • R 2 is H, d-C 6 alkyl, d-C 6 alkenyl, phenyl (d.C 6 ) alkyl, cycloalkyl (d-C 6 ) alkyl or cycloalkenyl (C ⁇ -C 6 ) alkyl group;
  • R 3 is an amino acid side chain or a d-C 6 alkyl, benzyl, (d-C 6 alkoxy) benzyl, benzyloxy (d-C 6 alkyl) or benzyloxybenzyl group;
  • R 4 is H or a d-C 6 alkyl group;
  • R 5 is H or a methyl group;
  • n is 0, 1 or 2; and
  • A represents a d-C 6 hydrocarbon chain, optionally substituted with one or more d-C 6 alkyl, phenyl or substituted phenyl groups; and their salts and N-oxides.
  • R 1 is H, d-C 6 alkyl, C 2 -C 6 alkenyl, phenyl, phenyl (d-C 6 ) alkyl, d-C 6 alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl (d-C 6 ) alkylthiomethyl, or heterocyclylthiomethyl or R 1 represents — SR* wherein R* represents a group
  • R 2 represents a hydrogen atom, or a d-C 6 alkyl, d-C 6 alkenyl, phenyl (d-C 6 ) alkyl, cycloalkyl (d-C 6 ) alkyl, or cycloalkenyl (d-C 6 ) alkyl;
  • R 3 represents an amino acid side chain or a d-C 6 alkyl, benzyl, (d-C 6 ) alkoxybenzyl, benzyloxy (d-C ⁇ ) alkyl, or benzyloxybenzyl group;
  • R 4 represents a hydrogen atom, or a methyl group;
  • n is an integer from 1 to 6; and
  • A represents the group — NH 2 , a substituted acyclic amine or a heterocyclic base; or a salt and/or N-oxide and/or (where the compound is a thio- compound) a sulphoxide or sulphone thereof.
  • R 1 is H, d-C 6 alkyl, d-C 6 alkenyl, phenyl, phenyl (C ⁇ -C 6 ) alkyl, d-C 6 alkylthiomethyl, phenylthiomethyl, substituted phenylthiomethyl, phenyl (d-C 6 ) alkylthiomethyl or heterocyclylthiomethyl group; or R 1 represents — S — R * , wherein R* represents a group
  • R 2 represents a hydrogen atom, or a d-C 6 alkyl, d-C 6 alkenyl, phenyl (d-C 6 ) alkyl, cycloalkyl (d-C ⁇ ) alkyl, or cycloalkenyl (d-C 6 ) alkyl;
  • R represents an amino acid side chain or a d-C 6 alkyl, benzyl, (d-C ⁇ ) alkoxybenzyl, benzyloxy (d-C ⁇ ) alkyl or benzyloxybenzyl group;
  • R represents a hydrogen atom or a methyl group;
  • R 5 represents a group (CH 2 ) friendshipA; or R 4 and R 5 together represent a group
  • Q represents CH 2 or CO; m is an integer from 1 to 3; n is an integer from 1 to 6; and A represents a hydroxy, (d-C 6 ) alkoxy, (C 2 -C ) acyloxy, (d-C 6 ) alkylthio, phenylthio, (C 2 -C 7 ) acylamino or N-pyrrolidone group; or a salt and/or N-oxide " and/or (where the compound is a thio-compound) a sulphoxide or sulphone thereof.
  • PCT International Publication No. WO91/02716 see, e.g., PCT International Publication No. WO91/02716.
  • R 1 is H, d-C 6 alkyl, phenyl, substituted phenyl, phenyl (d-C 6
  • R is ASOCENTR wherein A represents a d-C 6 hydrocarbon chain, optionally substituted with one or more d-C 6 alkyl, phenyl or substituted phenyl groups, n is 0, 1, or 2, and R is d-C 6 alkyl, phenyl, substituted phenyl, phenyl (d-C 6 alkyl), heterocyclyl, ( -C ⁇ alkyl) acyl, thienyl or phenacyl; R 2 is hydrogen, d-C 6 alkyl, d-C 6 alkenyl, phenyl (d-C 6 alkyl) or cycloalkyl (d-C 6 alkyl); R 3 and R 4 are selected from hydrogen, halogen, cyano amino, amino (d-C 6 ) alkyl, amino di (d-C 6 ) alkyl, amino (Cj .
  • R 3 is OCH 2 COR 8 and R 4 is hydrogen wherein R is hydroxyl, d-C 6 oxyalkyl, C ⁇ -C 6 oxyalkylphenyl, amino, d-
  • R 3 is OCH 2 CH 2 OR 9 and R 4 is hydrogen wherein R 9 is d-C 6 alkyl, d-C 6 alkylphenyl, phenyl, substituted phenyl, (d-C 6 alkyl)acyl, or phenacyl; or R 3 is OCH 2 CN and R 4 is hydrogen; R 5 is hydrogen or d-C 6 alkyl, or (d-C 6 ) alkylphenyl; R 6 is hydrogen or methyl; or a salt thereof.
  • PCT International Application No. PCT/GB92/00230 see, e.g., PCT International Application No. PCT/GB92/00230.
  • d-C alkyl refers to straight chain or branched chain hydrocarbon groups having from one to six carbon atoms, where illustrative alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl and hexyl.
  • d-C 6 alkenyl refers to straight chain or branched chain hydrocarbon groups having from one to six carbon atoms and having in addition one or more double bonds, each of either E or Z stereochemistry where applicable, where this term would include for example, an alpha, beta-unsaturated methylene, vinyl, 1 -propenyl, 1- and 2-butenyl and 2-methyl-2- propenyl, and where in a preferred embodiment the d-C 6 alkenyl group is a C 2 -C 6 alkenyl group.
  • C 3 -C 6 cycloalkyl refers to an alicyclic group having from 3 to 6 carbon atoms, where illustrative cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
  • C -C cycloalkenyl refers to an alicyclic group having from 4 to 6 carbon atoms and having in addition one or more double bonds, where illustrative cycloalkenyl groups are cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctenyl.
  • halogen refers to fluorine, chlorine, bromine or iodine.
  • amino acid side chain refers to a characteristic side chain attached to the -CH(NH )(COOH) moiety in the following R or S amino acids: glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cystein, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid and aspartic acid.
  • EP-A-0231081 EP-A- 0236872, EP-A-0274453, EP-A-0489577, EP-A-0489579, EP-A-0497192, EP-A- 0574758, and EP-A-0575844, as well as WO 90/05716, WO 90/05719, WO 91/02716, WO 92/09563, WO 92/17460, WO 92/13831, WO 92/22523, WO 93/09090, WO 93/09097, WO 93/20047, WO 93/24449, WO 93/24475, WO 94/02446, WO 94/02447, WO 94/21612, WO 94/21625, WO 94/24140, WO 94/25434, WO 94/25435, and WO 99/06361.
  • Many hydroxamates are also readily available from a variety of commercial sources.
  • polypeptide (including polypeptide derivative) inhibitors of matrix metalloproteinases can be utilized to extend the duration and utility of collagen.
  • polypeptide inhibitors include those disclosed in U.S. Patent Nos. 5,300,501, 5,530,128, 5,569,665, 5,714,491, and
  • Mercapto-based compounds can also be utilized as MMPIs.
  • Representative examples include mercaptoketon and mercaptoalcohol compounds such as those described in U.S. Patent Nos. 5,831,004, 5,840,698, and 5,929,278; and mercaptosulfides, such as those described in U.S. Patent No. 5,455,262.
  • Bisphosphonates are compounds which are related to inorganic pyrophosphonic acid (see generally H. Fleisch, Endocr. Rev., 7 (1):80-100 (1998); see also, H. Fleisch, Bisphosphonates in Bone Disease: From the Laboratory to the Patient (1997, 3rd ed.). The Parthenon Publishing Group, New York and London). Generally, bisphosphonates have the structure: P-C-P. Particularly preferred bisphosphonates have the structure
  • substituents R' and R" independently stand for a hydrogen or a halogen atom, a hydroxy, optionally substituted amino or optionally substituted thio group or an optionally substituted hydrocarbon residue.
  • one of R' and R" is hydroxy, hydrogen or chlorine.
  • bisphosphonates include, for example, alendronate ((4-amino-l-hydroxybutylidene) bisphosphonic acid); clodronate (dichloromethane bisphosphonic acid); etidronate ((1-hydroxyethylidene) bisphosphonic acid); pamidronate ((3-amino-l-hydroxypropylidene) bisphosphonic acid); risedronate ([-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid); tiludronate (([(4-chlorophenyl)thio]-methylene]bisphosphonic acid); zolendronate; [l-hydroxy-3- (methyl-pentylamino)-propylidene]bis-phosphonate; (BM21.0955, Boehringer Mannheim ); [(cycloheptylamino) methylene]bisphos-phonate (YM175); l-hydroxy-3- (1 -pyrrolidiny
  • more than one MMPI may be utilized (i.e., two or more MMPIs can be used in combination).
  • Synergistic MMPIs include, for example tetracyclines and bisphosphonates (see, e.g., U.S. Patent Nos. 5,998,390 and 6,114,316).
  • Other combinations of MMPIs can likewise be utilized, including for example, MMPIs which inhibit MMPs at different stages (e.g., hydroxamates and tetracyclines).
  • collagen is a fibrous protein that can be obtained from natural sources or produced recombinantly.
  • Representative examples of U.S. Patents which described collagen-based compositions and methods of preparing such compositions include U.S. Patent Nos. 6,166,130, 6,051,648, 5,874,500, 5,705,488, 5,550,187, 5,527,856, 5,523,291, 4,582,640, 4,424,208, and 3,949,073.
  • the MMPI compositions of the present invention can be prepared in a variety of ways.
  • the MMPI can be dissolved directly into the collagen solution. If the MMPI is stable in the collagen solution, the composition containing the collagen and the MMPI can be prepared in a single application apparatus. If the MMPI is not stable in the collagen solution for a significant length of time, the composition can be made as a two-component system in which the components are mixed immediately prior to use.
  • MMPI compositions of the present invention can also be generated by placing the MMPI in a carrier.
  • Representative examples of carriers include both polymeric and non-polymeric carriers (e.g., liposomes or vitamin-based carriers, whichi may be either biodegradable or non-biodegradable.
  • biodegradable compositions include albumin, gelatin, starch, cellulose, dextrans, polysaccharides, fibrinogen, poly(esters) [e.g., poly (D,L lactide), poly (D,L-lactide-co- glycolide), poly (glycolide), poly(e-caprolactone), copolymers and blends thereof] poly (hydroxybutyrate), poly (alkylcarbonate), poly(anhydrides) and poly (orthoesters) (see generally, Ilium, L., Davids, S.S. (eds.) "Polymers in controlled Drug Delivery” Wright, Bristol, 1987; Arshady, J., Controlled Release 17:1-22 (1991); Pitt, Int. J.
  • nondegradable polymers include copolymers of ethylene oxide and propylene oxide polymers, such as the PLURONIC polymers available from BASF Corporation (Mount Olive, NJ), EVA copolymers, silicone rubber, poly(methacrylate) based and poly(acrylate) based polymers.
  • Particularly preferred polymeric carriers include poly (D,L-lactic acid) oligomers and polymers, poly (L-lactic acid) oligomers and polymers, poly (glycolic acid), copolymers of lactic acid and glycolic acid, poly (caprolactone), poly (valerolactone), polyanhydrides, copolymers of caprolactone and/or lactic acid, and/or glycolic acid with polyethylene glycol or methoxypolyethylene glycol and blends thereof.
  • Polymeric carriers may be fashioned in a variety of forms, including for example, rod-shaped devices, pellets, slabs, or capsules (see, e.g., Goodell et al., Am. J. Hosp. Pharm.
  • MMPI may be linked by occlusion in the matrices of the polymer, bound by covalent linkages, or encapsulated in microcapsules.
  • MMPI compositions are provided in non-capsular formulations such as microspheres (ranging from nanometers to micrometers in size), pastes, threads of various size, films and sprays.
  • MMPI compositions of the present invention are fashioned in a manner appropriate to the intended use.
  • the MMPI composition should be biocompatible, and release one or more MMPI factors over a period of several days to months.
  • "quick release” or "burst" MMPI compositions are provided that release greater than 10%, 20%, or 25% of an MMPI factor (e.g., tetracycline) over a period of 7 to 10 days.
  • Such "quick release" compositions should, within certain embodiments, be capable of releasing chemotherapeutic levels (where applicable) of a desired MMPI factor.
  • MMPI compositions are provided that release less than 5% (w/v) of an MMPI factor over a period of 7 to 10 days. Further, MMPI compositions of the present invention should preferably be stable for several months and capable of being produced and maintained under sterile conditions.
  • MMPI compositions may be fashioned in any size ranging from about 0.050 nm to about 500 ⁇ m, depending upon the particular use. For example, when used for the purpose of cosmetic tissue augmentation (as discussed below), it is generally preferable to fashion the MMPI composition in microspheres of between about 0.1 to about 100 ⁇ m, preferably between about 0.5 and about 50 ⁇ m, and most preferably, between about 1 and about 25 ⁇ m. Alternatively, such compositions may also be applied as a solution in which the MMPI is solubilized in a micelle.
  • the composition of the micelles may be polymeric in nature.
  • polymeric micelles may include a copolymer of MePEG and poly(D,L- lactide).
  • compositions may also be applied as a solution in which the MMPI is encapsulated in a liposome (see above).
  • compositions may also be applied as a solution in which the MMPI is encapsulated in the oil phase of an emulsion or microemulsion.
  • MMPI compositions of the present invention may also be prepared in a variety of "paste" or gel forms.
  • MMPI compositions are provided which are liquid at one temperature (e.g., temperature greater than 37°C, such as 40°C, 45°C, 50°C, 55°C or 60°C), and solid or semi-solid at another temperature (e.g., ambient body temperature, or any temperature lower than 37°C).
  • temperature e.g., temperature greater than 37°C, such as 40°C, 45°C, 50°C, 55°C or 60°C
  • solid or semi-solid e.g., ambient body temperature, or any temperature lower than 37°C.
  • polymeric carriers which are adapted to contain and release a hydrophobic compound, the carrier containing the hydrophobic compound in combination with a carbohydrate, protein or polypeptide.
  • the polymeric carrier contains or comprises regions, pockets, or granules of one or more hydrophobic compounds.
  • hydrophobic compounds may be mcorporated within a matrix that contains the hydrophobic compound, followed by incorporation of the matrix v thin the polymeric carrier.
  • hydrophobic compounds may be contained within a hydrophobic core, and this core contained within a hydrophilic shell.
  • paclitaxel may be incorporated into a hydrophobic core (e.g., of the poly D,L lactic acid-PEG or MePEG aggregate) which has a hydrophilic shell.
  • MMPI compositions may be fashioned in such a manner that the MMPI is covalently attached to the collagen used in the specific application.
  • the MMPI can be attached directly to the collagen or through a linker molecule (e.g., poly(ethylene glycol)).
  • linker molecule e.g., poly(ethylene glycol)
  • the conjugate i.e., prodrug
  • the MMPI may inhibit the MMP while still attached to the collagen or it may inhibit the MMP after it has been cleaved (hydrolytic and/or enzymatic cleavage) from the collagen.
  • a heterobifunctional crosslinking agent e.g., Sulfo- EMCS [Pierce Chemical Co., Rockford, IL]
  • Sulfo-EMCS Piercece Chemical Co., Rockford, IL
  • the TIMP can be reacted with Sulfo-EMCS such that the maleimide group reacts with the -SH group of the cysteine contained with in the TIMP sequence.
  • the activated TIMP can then be reacted with a collagen solution.
  • the collagen-TIMP conjugate can then be used for tissue augmentation applications.
  • compositions provided herein may be further modified in order to enhance their utility.
  • a dye or other coloring agent may be added to enhance visualization of the composition.
  • the dye or coloring agent may be either permanent, or transient (e.g., methylene blue).
  • compounds or factors which aid clotting e.g., thrombin may be added to the compositions described herein.
  • compositions provided herein may further include additional compounds or agents that encourage or stimulate bone growth, including for example, hydroxyapatite and/or bone morphogenic proteins (e.g., BMP-1 to BMP-9), which are described, for example, in U.S. Patent Nos. 4,877,864; 5,013,649; 5,661,007; 5,688,678; 6,177,406; 6,432,919; and 6,534,268; and Wozney, J.M., et al., Science: 242(4885): 1528-1534 (1988).
  • hydroxyapatite and/or bone morphogenic proteins e.g., BMP-1 to BMP-9
  • Collagen is the principle organic component of bone and can be combined with mineral formulations, autogenous bone marrow, bone graft, and/or growth factors (such as BMPs) for use as a bone substitute or a skeletal repair product.
  • Typical applications include, but are not restricted to, total joint replacement surgery (e.g. artificial hips, knees, etc.), spinal fusion surgery, long bone fractures, repair of traumatic bone defects, voids, or gaps, to augment an autograph, and as a bone filler at bone graft harvesting sites.
  • COLLAGRAFT is a combination of highly purified Type I bovine dermal fibrillar collagen and a mixture of 65% hydroxyapatite and 35% tricalcium phosphate. This material closely resembles human bone and is resorbed and replaced with bone during the healing process.
  • Representative examples of bone grafts are described in U.S. Patents No. 6,083,522 and 6,280,474, and in PCT publication No. WO 98/52498.
  • an MMPI is added to the collagen matrix in a sustained-release form to decrease the rate of degradation of the bone graft material and prolong its activity in vivo beyond that seen with collagen alone. This allows the matrix to function as a scaffold for longer periods of time allowing stronger, more mature bone growth to occur prior to dissolution of the collagen matrix. Any MMPI described above could be utilized alone, or in combination, in the practice of this embodiment.
  • Preferred MMPFs for use in bone grafts include TIMP-1, tetracycline, doxycycline, minocycline, and other chemically-modified tetracyclines (CMTs), BATIMISTAT, MARIMISTAT, RO-1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE, as well as analogues and derivatives of the aforementioned. All of these agents are suitable for use in combination with factors that encourage bone growth including, but not restricted to, BMPs (e.g. BMP-2), autogenous marrow, mineral, and autologous bone graft material. The following particularly preferred compositions are ideally suited for use in this indication.
  • BMPs e.g. BMP-2
  • autogenous marrow e.g. BMP-2
  • mineral e.g
  • the preferred MARIMASTAT-loaded collagen bone graft matrix is about 0.001% -30% MARIMASTAT by weight (i.e., l ⁇ g - 30mg MARIMASTAT per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 15% MARIMASTAT by weight (i.e., lO ⁇ g - 15mg per lOOmg of collagen paste).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of MARIMASTAT using this dosing regimen is l ⁇ g - 37.5 ⁇ g/mm 2 of collagen strip.
  • the total dosage delivered in a MARIMASTAT -loaded collagen orthopedic implant procedure would typically not exceed 45 mg (or less than the established well tolerated single daily does of 50 mg).
  • 0.001 - 30% MARIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • pharmaceutically acceptable analogues and derivatives of MARIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • the preferred BATIMASTAT -loaded collagen bone graft matrix - is 0.001 - 30% BATIMASTAT by weight (i.e., lug - 30mg BATIMASTAT per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 to 30% by weight (lO ⁇ g - 30mg per lOOmg of collagen paste).
  • drug dosage can also be determined as a function of area. Preferred dosing of BATIMASTAT using this dosing regimen is l ⁇ g - 200 ⁇ g/mm 2 of collagen strip.
  • the total dosage delivered in a BATIMASTAT -loaded collagen orthopedic implant procedure would not exceed 240 mg of BATIMASTAT (or less than the established well tolerated single dose of 300 mg/m 2 ).
  • 0.001 - 30% BATIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of BATIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Doxycycline-loaded collagen bone graft matrix The preferred doxycycline-loaded collagen bone graft matrix is 0.001 -
  • 30% doxycycline by weight lug - 30mg doxycycline per lOOmg of collagen implant.
  • a particularly preferred dosage is 0.01 - 30% doxycycline by weight (lO ⁇ g - 30mg doxycycline per lOOmg of collagen paste).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of doxycycline using this dosing regimen is l ⁇ g-83 ⁇ g/mm 2 of collagen strip.
  • the total dosage delivered in a doxycycline-loaded collagen orthopedic implant procedure should typically not exceed 150 mg of doxycycline (or less than the established well tolerated single dose of 200mg).
  • doxycycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of doxycycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred tetracycline-loaded collagen bone graft matrix is 0.001 - 30%) tetracycline by weight (lug - 30mg tetracycline per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 30% tetracycline by weight (lO ⁇ g - 30mg tetracycline per lOOmg of collagen paste).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of tetracycline using this dosing regimen is l ⁇ g-625 ⁇ g/mm of collagen strip.
  • the total dosage delivered in a tetracycline-loaded collagen orthopedic implant procedure should typically not exceed 750 mg of tetracycline (or less than the established well tolerated single dose of lOOOmg).
  • 0.001 - 30% tetracycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Parmaceutically acceptable analogues and derivatives of tetracycline, including chemically-modifed tetracylines (CMTs) are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred minocycline-loaded collagen bone graft matrix is 0.001 - 30%) minocycline by weight (l ⁇ g - 30mg minocycline per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 6% minocycline by weight (10 ⁇ g - 6 mg minocycline per lOOmg of collagen paste).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of minocycline using this dosing regimen is l ⁇ g-150 ⁇ g/mm of collagen strip.
  • the total dosage delivered in a minocyline-loaded collagen orthopedic implant procedure should typically not exceed 180 mg of minocycline (or less than the established tolerated single dose of 200mg).
  • 0.001 - 30% minocycline is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of minocycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • TROCADE-loaded collagen bone graft matrix A preferred TROCADE-loaded collagen bone graft matrix is 0.001 - 30% TROCADE by weight (l ⁇ g - 30mg TROCADE per lOOmg of collagen implant). A particularly preferred dosage is 0.01 to 5% TROCADE by weight (lO ⁇ g - 5mg TROCADE per lOOmg of collagen paste). Alternatively, since the material is often packaged as a strip, drug dosage can also be determined as a function of area. Preferred dosing of TROCADE using this dosing regimen is l ⁇ g - 100 ⁇ g/mm 2 of collagen strip.
  • the total dosage delivered in a TROCADE-loaded collagen orthopedic implant procedure should typically not exceed 120mg of TROCADE (or less than the established well tolerated single dose of 150mg).
  • 0.001 - 30% TROCADE by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TROCADE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Implantable medical devices containing collagen sponges have been developed to improve the outcome of spinal fusion surgery. When conservative management of degenerative disc disease is ineffective, it often becomes necessary to surgically fuse together the adjacent bony lumbar segments on either side of an affected disc.
  • An example of a collagen-containing medical device used in spinal fusion surgery is the LT-CAGE and INFUSE Bone Graft system developed by Medtronic Sofamor Danek, Inc. (Memphis, TN).
  • the LT-CAGE system is a threaded metallic cylinder with a hollow core which is placed across the diseased disc and anchored into the vertebrae above and below it.
  • the surgeon accesses the spine and removes a portion of the degenerated disc from the affected disc space.
  • the metal cage is then placed into the disc space to provide support and restore normal anatomic positioning to the spine until bone fusion occurs.
  • the hollow core of the cage allows the placement of materials, such as autologous bone grafts and bone morphogenic proteins (BMPs), that will encourage bone ingrowth.
  • BMPs bone morphogenic proteins
  • Type I bovine absorbable collagen sponge is used as a carrier for the INFUSE recombinant bone morphogenic protein-2 (BMP-2) (available from Medtronic Sofamor Danek).
  • BMP-2 bone morphogenic protein-2
  • the collagen sponge is hydrated with a solution containing BMP-2, rolled up and placed into the cage prior to its placement into the disc space. Once in place, the BMP is slowly released from the collagen matrix to stimulate bone growth, while the matrix itself acts as a scaffold for the deposition of new bone.
  • an MMPI is added to a collagen sponge in a sustained-release form to decrease the rate of degradation of the implant and prolong its activity in vivo beyond that seen with collagen alone. This would allow the matrix to function as a scaffold for longer periods of time allowing stronger, more mature bone growth to occur prior to dissolution of the collagen matrix.
  • MMPI any MMPI described previously could be utilized alone, or in combination, in the practice of this embodiment.
  • Representative MMPI's for use in spinal implants include TIMP-1, tetracycline, doxycycline, minocycline, and other chemically-modified tetracyclines (CMTs), BATIMASTAT, MARIMASTAT, RO- 1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP- 544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE, as well as analogues and derivatives of the aforementioned.
  • CMTs chemically-modified tetracyclines
  • BMPs e.g. BMP-2 or BMP-8
  • autologous bone graft material e.g. BMP-2 or BMP-8
  • the following particularly preferred compositions are ideally suited for use in this indication: a. MARIMASTAT-loaded collagen spinal implants
  • a preferred MARIMASTAT -loaded spinal collagen implant is 0.001% - 30% MARIMASTAT by weight (i.e., l ⁇ g - 30mg MARIMASTAT per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 15% MARIMASTAT by weight (i.e., lO ⁇ g - 15mg per lOOmg of collagen implant).
  • Preferred dosing of MARIMASTAT using this dosing regimen is l ⁇ g - 37.5 ⁇ g/mm of collagen implant.
  • the total dosage delivered in spinal fusion treatment should typically not exceed 45 mg (or less than the established well tolerated single daily does of 50 mg).
  • 0.001 - 30% MARIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of MARIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% BATIMASTAT by weight (i.e., l ⁇ g - 30mg BATIMASTAT per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 to 30% by weight (lO ⁇ g - 30mg per lOOmg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of BATIMASTAT using this dosing regimen is l ⁇ g - 200 ⁇ g/mm of collagen implant.
  • the total dosage delivered in a BATIMASTAT -loaded collagen spinal implant should typically not exceed 240 mg of BATIMASTAT (or less than the established well tolerated single dose of 300 mg/m 2 ).
  • 0.001 - 30% BATIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non- crosslinked
  • Pharmaceutically acceptable analogues and derivatives of BATIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% doxycycline by weight-(lug - 30mg doxycycline per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 30%) doxcycline by weight (lO ⁇ g - 30mg doxycycline per lOOmg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of doxycycline using this dosing regimen is l ⁇ g-83 ⁇ g/mm 3 of collagen implant.
  • the total dosage delivered in a doxycycline-loaded collagen spinal implant should typically not exceed 100 mg of doxycycline (or less than the established well tolerated single dose of 200mg).
  • 0.001 - 30% doxycycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of doxycycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Tetracycline-loaded collagen spinal implants A preferred composition is 0.001 - 30% tetracycline by weight (lug - 30mg tetracycline per lOOmg of collagen implant). A particularly preferred dosage is 0.01 - 30%) tetracycline by weight (lO ⁇ g - 30mg tetracycline per 100 mg of collagen implant). Alternatively, since the material is often packaged as a sheet, drug dosage can also be determined as a function of area. Preferred dosing of tetracycline using this dosing regimen is l ⁇ g-625 ⁇ g/mm 3 of collagen implant.
  • the total dosage delivered in a tetracycline-loaded collagen spinal implant should typically not exceed 750 mg of tetracycline (or less than the established well tolerated single dose of 1000 mg).
  • 0.001 - 30% tetracycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of tetracycline, including chemically-modifed tetracylines (CMTs) are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Minocycline-loaded collagen spinal implants A preferred composition is 0.001 - 30% minocycline by weight (l ⁇ g -
  • a particularly preferred dosage is 0.01 - 6% minocycline by weight (10 ⁇ g - 6 mg minocycline per 100 mg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of minocycline using this dosing regimen is l ⁇ g- 150 ⁇ g/mm of collagen implant.
  • the total dosage delivered in a collagen spinal implant should typically not exceed 180 mg of minocycline (or less than the established tolerated single dose of 200mg).
  • 0.001 - 30% minocycline is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of minocycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% TROCADE by weight (l ⁇ g - 30mg TROCADE per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 to 5% TROCADE by weight (lO ⁇ g - 5mg TROCADE per 100 mg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of TROCADE using this dosing regimen is l ⁇ g - lOO ⁇ g/mm 3 of collagen implant.
  • the total dosage delivered in a TROCADE-loaded collagen spinal implant should typically not exceed 120mg of TROCADE (or less than the established well tolerated single dose of 150mg).
  • 0.001 - 30% TROCADE by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TROCADE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Surgical slings such as the FORTAFLEX Surgical Sling (Organogenesis Inc., Canton, MA) and the SURGISIS Sling are also composed predominantly of Type I Collagen (usually porcine or bovine) and are utilized in open urological surgery procedures. Indications include pubourethral support, prolapse repair (urethral, vaginal, rectal and colonic), rectoceles, cystoceles, enteroceles, mastoplexy, reconstruction of the pelvic floor, bladder support, sacrocolposuspension and other reconstructive procedures.
  • Indications include pubourethral support, prolapse repair (urethral, vaginal, rectal and colonic), rectoceles, cystoceles, enteroceles, mastoplexy, reconstruction of the pelvic floor, bladder support, sacrocolposuspension and other reconstructive procedures.
  • Collagen surgical patches are also be used in tendon, ligament and cartilage repair surgeries. Over 700,000 ligament and tendon repairs are performed annually in the United States including: repairs of the foot and ankle (11% of the total - particularly the Achilles tendon; also peroneal tendons, plantar fascia repair, extensor digitorum tendons, anterior tibial tendon, lateral stailizing ligaments of the ankle, anterior inferior tibial fibular ligament, medial deltoid ligament), knee (38% of the total - particularly the medial collateral ligament, lateral collateral ligament, anterior cruciate ligament, posterior cruciate ligament, meniscal repair; also chondral surface repair, patellar tendon repair, bicep femoris tendon repair), hip (rectus femoris origin ⁇ gracilis tendon, avulsion of the hamstring muscle origins), pelvis (gracilis muscle origin, adductor muscle origins, rectus femoris insertion, pubic symphysis carti
  • Collagenous patches such as the FORTAFLEX Patch, are used to reinforce the tissue during surgical repair and healing. Tendon and ligament repair surgeries typically involve the use of suture anchors or suture-passing devices to secure the damaged tendons to the bone. Depending on the size of the tear, a collagen patch may be used to fill a defect in the tendon or ligament.
  • the collagen implant serves as a resorbable scaffold that provides biomechanical strength, support and reinforcement of soft tissues that are surgically repaired. Eventually the collagen becomes infiltrated and replaced by host tissue cells which are able to repair and regenerate the damaged tissue. For many of these surgical interventions, durability of the collagen implant becomes an important clinical issue. In urinary procedures, the surgical correction of tissue defects (particularly abdominal wall and hernia repairs) and in tendon and ligament repairs, it is desirable for the collagen implant to provide structural integrity until full healing can occur. In the case of large tissue defects, which can take several months to over a year to heal, limited durability of the collagen implant can become a clinical problem if it completely absorbs prior to the completion of healing.
  • MMPI any MMPI described above could be utilized alone, or in combination, in the practice of this embodiment.
  • Preferred MMPI's for use as surgical meshes, slings and patches include TIMP-1, tetracycline, doxycycline, minocycline, and other chemically-modified tetracyclines (CMTs), BATIMASTAT, MARIMASTAT, RO- 1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP- 544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE, as well as analogues and derivatives of the aforementioned.
  • CMTs chemically-modified tetracyclines
  • BATIMASTAT MARIMASTAT
  • RO- 1130830 RO- 1130830
  • CGS 27023A CGS 27023A
  • BMS-275291 CMT-3
  • a preferred MARIMASTAT -loaded collagen surgical mesh, slings and patches is 0.001% - 30% MARIMASTAT by weight (i.e., l ⁇ g - 30mg MARIMASTAT per lOOmg of surgical mesh, sling or patch).
  • a particularly preferred dosage is 0.01 - 15% MARIMASTAT by weight (i.e., lO ⁇ g - 15mg per lOOmg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of MARIMASTAT using this dosing regimen is l ⁇ g - 104 ⁇ g/cm 2 of collagen sheet.
  • the total dosage delivered in a soft tissue repair should typically not exceed 45 mg (or less than the established well tolerated single daily does of 50 mg). Regardless of the size or type of collagen implant employed (surgical mesh, sling or patch), the total drug content should typically not exceed 50mg of MARIMASTAT.
  • 0.001 - 30% MARIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of MARIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% BATIMASTAT by weight (i.e., lug - 30mg BATIMASTAT per lOOmg of collagen surgical mesh, sling or patch).
  • a particularly preferred dosage is 0.01 to 30% by weight (lO ⁇ g - 30mg per lOOmg of collagen surgical mesh, sling or patch).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of BATIMASTAT using this dosing regimen is l ⁇ g - 555 ⁇ g/cm 2 of collagen implant.
  • the total dosage delivered in a 12cm x 36cm BATIMASTAT -loaded collagen surgical implant should typically not exceed 240 mg of BATIMASTAT (or less than the established well tolerated single dose of 300 mg/m 2 ). Regardless of the size or type of collagen implant employed (surgical mesh, sling or patch), the total drug content-should typically not exceed 300mg of BATIMASTAT.
  • 0.001 - 30% BATIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of BATIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30%) doxycycline by weight (l ⁇ g - 30mg doxycycline per lOOmg of collagen surgical mesh, sling or patch).
  • a particularly preferred dosage is 0.01 - 30% doxcycline by weight-(10 ⁇ g - 30mg doxycycline per 100 mg of collagen surgical mesh, sling or patch).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of doxycycline using this dosing regimen is l ⁇ g - 350 ⁇ g/cm 2 of collagen implant.
  • the total dosage delivered in a 12cm x 36cm doxycycline-loaded collagen surgical implant would typically not exceed 160 mg of doxycycline (or less than the established well tolerated single dose of 200mg).
  • the total drug content should typically not exceed 200mg of doxycycline.
  • 0.001 - 30%> doxycycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of doxycycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30%> tetracycline by weight (l ⁇ g - 30mg tetracycline per lOOmg of collagen surgical mesh, sling or patch).
  • a particularly preferred dosage is 0.01 - 30%) tetracycline by weight (10 ⁇ g - 30 mg tetracycline per lOOmg of collagen surgical mesh, sling or patch).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of tetracycline using this dosing regimen is 1 ⁇ g - 1.75 mg/cm of collagen implant. Therefore, the total dosage delivered in a 12cm x 36cm tetracycline-loaded collagen surgical implant would typically not exceed 760 mg of tetracycline (or less than the established well tolerated single dose of 1000 mg). Regardless of the size or type of collagen implant employed (surgical mesh, sling or patch), the total drug content should typically not exceed 1000 mg of tetracycline. In one embodiment, 0.001 - 30% tetracycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of tetracycline, including chemically-modifed tetracylines (CMTs) are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% minocycline by weight (l ⁇ g -
  • a particularly preferred dosage is 0.01 - 6% minocycline by weight (10 ⁇ g - 6 mg minocycline per lOOmg of collagen surgical mesh, sling or patch).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of minocycline using this dosing regimen is l ⁇ g - 415 ⁇ g/cm of collagen implant.
  • the total dosage delivered in a 12cm x 36cm minocycline-loaded collagen surgical-implant would typically not exceed 180 mg of minocycline (or less than the established tolerated single dose of 200mg). Regardless of the size or type of collagen implant employed (surgical mesh, sling or patch), the total drug content should typically not exceed 200mg of minocycline.
  • 0.001 - 30% minocycline is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of minocycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% TROCADE by weight (l ⁇ g -
  • TROCADE per lOOmg of collagen surgical mesh, sling or patch 30mg TROCADE per lOOmg of collagen surgical mesh, sling or patch).
  • a particularly preferred dosage is 0.01 to 5% TROCADE by weight (lO ⁇ g - 5mg TROCADE per lOOmg of collagen surgical mesh, sling or patch).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of TROCADE using this dosing regimen is l ⁇ g - 275 ⁇ g/cm 2 of collagen implant.
  • the total dosage delivered in a 12cm x 36cm TROCADE-loaded collagen surgical implant would typically not exceed 120mg of TROCADE (or less than the established well tolerated single dose of 150mg). Regardless of the size or type of collagen implant employed (surgical mesh, sling or patch), the total drug content should typically not exceed 150mg of TROCADE.
  • 0.001 - 30% TROCADE by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TROCADE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Implantable collagen is often used in dental procedures to fill tissue defects and to promote healing and tissue regeneration.
  • the embodiment described below details compositions of metalloprotemase inhibitor-loaded collagen products and methods for their use in the treatment of common periodontal conditions according to the present invention.
  • periodontal disease is an inflammatory disease of the supporting structures of the teeth, including the ligaments, cementum, periosteum, alveolar bone and adjacent gingiva which anchor the teeth in place.
  • the condition begins with bleeding of the gums, but can progress to loosening of the teeth, receding gums, abscesses in pockets between the gums and the teeth, and necrotizing uleerative gingivitis.
  • procedures such as gingivectomy, gingivoplasty, and correction of the bony architecture of the teeth may be required for treatment of the condition.
  • Traditional treatment involves open-flap debridement of the periodontal pocket with removal of diseased cementum, periodontal ligament and alveolar bone that have been destroyed by periodontal infection.
  • Collagen implants have been developed in an attempt to control the healing process and optimize tissue regeneration.
  • Commonly used implants include, e.g., BIOMEND, available from Sulzer Medica, Inc. (Houston, TX), which is a collagen membrane composed of compressed Type I collagen matrix derived from bovine Achilles tendon.
  • the collagen membrane (supplied as sheets, e.g., 15mm x 20mm; 20mm x 30mm; and 30mm x 40mm) is cut to the appropriate size and shape, hydrated and placed as a barrier between the overlying gingival tissue and the debrided periodontal defect; the barrier can be sutured in place, but this is not always required.
  • the membrane is placed snugly against the tooth root and draped over the surrounding alveolar bone (extending at least 3mm beyond the defect margins) to effectively maintain the regenerative space.
  • Primary closure with mucoperiosteal flaps over the collagen membrane is important as exposure of the membrane to the oral cavity can result in premature degradation.
  • the barrier prevents faster growing epithelial tissue from entering the region and allows the slower growing periodontal ligament and bone cells to repopulate the area and effect appropriate healing.
  • the collagen membrane is bioresorbable, is retained for 6 to 7 weeks, and is fully absorbed by host enzymes (e.g., collagenase) within 8 weeks.
  • host enzymes e.g., collagenase
  • limited durability of the collagen implant can become a clinical problem if it completely absorbs prior to the completion of healing - this is particularly relevant with large tissue defects.
  • manufacturers have attempted to produce a collagen implant with improved durability through increased collagen crosslinking (often through exposure of the collagen to aldehydes).
  • BIOMEND EXTEND Sud Medica, Inc.
  • BIOMEND EXTEND Stem Medica, Inc.
  • Another collagen dental implant product, OSSLX Coldbar R&D Ltd., Israel
  • OSSLX Coldbar R&D Ltd., Israel
  • Utilizing a MMPI-loaded collagen dental implant according to the present invention can sustain the activity of the barrier, prolong structural integrity of the matrix, and allow more effective healing of the periodontal tissue defect.
  • the implant will still ultimately degrade, but will last for longer than currently available biodegradable collagen implants regardless of the degree (or type) of collagen crosslinking present.
  • This embodiment is also superior to permanent implants, such as e-PTFE membranes (e.g., GORE-TEX), which can require a second operative procedure to remove the implant.
  • collagen-based implants may be combined with an MMPI and used in the practice of the present invention.
  • Representative examples of such implants include those that are used in variety of dental procedures including: COLLATAPE (Sulzer Medica, Inc.), which is a collagen-based implant used in the repair of minor oral wounds, closure of grafted sites and repair of Schneiderian Membranes; COLLACOTE (Sulzer Medica, Inc.), a collagen-based wound dressing used for palatal donor sites and in mucosal flaps; and COLLAPLUG (Sulzer Medica, Inc.), a solid collagen-based implant used in the repair of larger tissue defects such extraction sites or biopsy sites.
  • an MMPI may be added to the collagen-based dental implant in a sustained-release form to decrease the rate of degradation of the implant and prolong its activity in vivo beyond that seen with collagen alone (e.g. consistently greater than 10 weeks for certain applications (such as oral wounds, grafted sites, repair of Schneiderian membranes), beyond 20 weeks in other applications (such as mucosal flaps, periodontal disease without alveolar bone loss, periodontal disease with minor bone loss), and for 6 months to a year for other- indications (such as periodontal disease with significant alveolar bone loss)).
  • certain applications such as oral wounds, grafted sites, repair of Schneiderian membranes
  • mucosal flaps such as mucosal flaps, periodontal disease without alveolar bone loss, periodontal disease with minor bone loss
  • 6 months to a year for other- indications such as periodontal disease with significant alveolar bone loss
  • MMPI any MMPI described above could be utilized alone, or in combination, in the practice of this embodiment.
  • Preferred MMPI's for use in dental implants include TIMP-1, tetracycline, doxycycline, minocycline, and other chemically-modified tetracyclines (CMTs), BATIMASTAT, MARIMASTAT, RO-1130830, CGS 27023 A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE, as well as analogues and derivatives of the aforementioned.
  • CMTs chemically-modified tetracyclines
  • BATIMASTAT MARIMASTAT
  • RO-1130830 CGS 27023 A
  • BMS-275291 CMT-3
  • SOLIMASTAT SOLIMASTAT
  • ILOMASTAT ILOMASTAT
  • a preferred MARIMASTAT-loaded dental collagen implant is 0.001% -
  • 30% MARIMASTAT by weight i.e., l ⁇ g - 30mg MARIMASTAT per lOOmg of collagen implant.
  • a particularly preferred dosage is 0.01 - 15%> MARIMASTAT by weight (i.e., lO ⁇ g - 15mg per lOOmg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of MARIMASTAT using this dosing regimen is l ⁇ g - 37.5 ⁇ g/mm 2 of collagen implant.
  • the total dosage delivered in periodontal treatment would typically not exceed 45 mg (or less than the established well tolerated single daily does of 50 mg).
  • the total drug content should typically not exceed 50mg of MARIMASTAT.
  • 0.001 - 30% MARIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of MARIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% BATIMISTAT by weight (i.e., lug - 30mg BATIMISTAT per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 to 30% by weight (lO ⁇ g - 30mg per lOOmg of collagen implant).
  • drag dosage can also be determined as a function of area.
  • Preferred dosing of BATIMISTAT using this dosing regimen is l ⁇ g - 200 ⁇ g/mm 2 of collagen implant.
  • the total dosage delivered in a 30mm x 40mm BATIMISTAT -loaded collagen dental implant would typically not exceed 240 mg of BATIMISTAT (or less than the established well tolerated single dose of 300 mg/m 2 ).
  • the total drug content should typically not exceed 300mg of BATIMISTAT.
  • 0.001 - 30% BATIMISTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, 1 or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of BATIMISTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% doxycycline by weight (lug - 30mg doxycycline per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 30% doxcycline by weight (lO ⁇ g - 30mg doxycycline per lOOmg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of doxycycline using this dosing regimen is l ⁇ g-83 ⁇ g/mm 2 of collagen implant.
  • the total dosage delivered in a 30mm x 40mm doxycycline-loaded collagen dental implant would typically not exceed 100 mg of doxycycline (or less than the established well tolerated single dose of 200mg). Regardless of the size or type of collagen implant employed (sheet, tape, plug or tissue filler) the total drug content should typically not exceed 200mg of doxycycline.
  • 0.001 - 30% doxycycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drag over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Parmaceutically acceptable analogues and derivatives of doxycycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% tetracycline by weight (lug - 30mg tetracycline per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 30%) tetracycline by weight (lO ⁇ g - 30mg tetracycline per lOOmg of collagen implant).
  • drug dosage can also be determined as a function of area.
  • Preferred dosing of tetracycline using this dosing regimen is l ⁇ g-625 ⁇ g/mm 2 of collagen implant.
  • the total dosage delivered in a 30mm x 40mm tetracycline-loaded collagen dental implant would typically not exceed 750 mg of tetracycline (or less than the established well tolerated single dose of lOOOmg). Regardless of the size or type of collagen implant employed (sheet, tape, plug or tissue filler) the total drag content should typically not exceed lOOOmg of tetracycline. In one embodiment, 0.001 - 30% tetracycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of tetracycline, including chemically-modifed tetracylines (CMTs) are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% minocycline by weight (l ⁇ g - 30mg minocycline per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 - 6% minocycline by weight (10 ⁇ g - 6 mg minocycline per lOOmg of collagen implant).
  • drag dosage can also be determined as a function of area.
  • Preferred dosing of minocycline using this dosing regimen is l ⁇ g-150 ⁇ g/mm of collagen implant.
  • the total dosage delivered in a 30mm x 40mm minocycline-loaded collagen dental implant would typically not exceed 180 mg of minocycline (or less than the established tolerated single dose of 200mg). Regardless of the size or type of collagen implant employed (sheet, tape, plug or tissue filler) the total drug content should typically not exceed 200mg of minocycline.
  • 0.01 - 30% minocycline is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • compositions are 0.001 - 30% TROCADE by weight (lug - 30mg TROCADE per lOOmg of collagen implant).
  • a particularly preferred dosage is 0.01 to 5% TROCADE by weight (lO ⁇ g - 5mg TROCADE per lOOmg of collagen implant).
  • drag dosage can also be determined as a function of area.
  • TROCADE using this- dosing regimen is l ⁇ g - lOO ⁇ g/mm of collagen implant.
  • the total dosage delivered in a 30mm x 40mm TROCADE-loaded collagen dental implant would typically not exceed 120mg of TROCADE (or less than the established well tolerated single dose of 150mg).
  • the total drug content should typically not exceed 150mg of TROCADE.
  • 0.001 - 30% TROCADE by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TROCADE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • ORCEL Bilayered Cellular Matrix (Ortec International, Inc., New York, NY) is composed of purified bovine Type I collagen mixed with two types of living human skin cells. ORCEL is a wound dressing applied to the wound surface to promote healing before gradually being absorbed.
  • a related product, Composite Cultured Skin (Ortec International, Inc.), is a wound dressing composed of purified bovine Type I collagen mixed with human skin cells taken from healthy donors for use in the management of recessive dystrophic epidermolysis bullosa (RDEB).
  • RDEB recessive dystrophic epidermolysis bullosa
  • APLIGRAF (Organogenesis Inc., Canton, MA) is a living, bilayered skin substitute manufactured using neonatal foreskin keratmocytes and fibroblasts with bovine Type I collagen. It is indicated for the treatment of partial and/or full-thickness skin ulcers such as venous leg ulcers and diabetic foot ulcers.
  • Representative examples of skin grafts and methods for preparing artificial skin are described in U.S. Patent Nos. 5,166,187, 5,263,983, 5,326,356, 5,350,583, 5,800,811, and 5,945,101.
  • differential loading of an MMPI into a collagen-based skin graft may be used for accurately controlling the dissolution rate of the graft.
  • the present invention provides a collagen-based skin -graft in combination with an MMPI.
  • metalloprotemase inhibitors could be suitable for incorporation into a collagen-based skin graft, the following are particularly preferred: TIMP-1, tetracycline, chemically- modified tetraclines (CMTs), doxycycline, minocycline, BATIMASTAT, MARIMASTAT, RO-1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE, as well as analogues or derivatives of the aforementioned.
  • dissolution can be varied from 12 hours to 72 hours and beyond.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked is suitable for production of the above product.
  • Corneal shields are used post-operatively, usually following cataract surgery, to function as a splint to facilitate healing by immobilizing and protecting scleral and conjunctival tissue. Corneal shields provide continuous lubrication to compromised tissue while providing a protective barrier and increasing patient comfort. Varieties of collagen-based corneal shields are available for this clinical use and differ primarily by their duration of activity.
  • the SURGILENS shield (Bausch & Lomb, Inc., Rochester, NY) is a rapidly dissolving lens which is completely resorbed in 12 hours. Oasis Medical Inc.
  • corneal shields make several different collagen corneal shields including: the SOFT SHIELD QS; the SOFT SHIELD, 12-hour (12 hour dissolution time); the SOFT SHIELD, 24-hour (24 hour dissolution time); and the SOFT SHIELD, 72-hour (72 hour dissolution time).
  • Alcon Laboratories, Inc. (Fort Worth, TX) also manufactures a line of collagen corneal shields, known as PROSHIELD, that are available in a wide range of dissolution rates. Representative examples of corneal shields are described in U.S. Patent Nos. 6,106,554 5,128,134, 5,094,856, 5,094,855, 5,093,125, and 4,913,904.
  • differential loading of an MMPI into a collagen corneal shield may be used for accurately controlling the dissolution rate of the shield.
  • the present invention provides a collagen- containing corneal shield in combination with an MMPI.
  • any of the previously described metalloprotemase inhibitors could be suitable for incorporation into a collagen corneal shield, the following are particularly preferred: TIMP-1, tetracycline, chemically-modifed tetracylines (CMTs), doxycycline, minocycline, BATIMASTAT, MARIMASTAT, RO-1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, SU-5402 and TROCADE, as well as analogues and derivatives of the aforementioned.
  • dissolution can be varied from 12 hours to 72 hours and beyond.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked is suitable for production of the above product.
  • Collagen-based glaucoma drainage devices are used in the surgical management of open-angle glaucoma.
  • Glaucoma is a common eye condition in which pressure within the eyeball (intraocular pressure - IOP) increases to the point where retinal tissues can be damaged (occasionally to the point of causing blindness).
  • IOP intraocular pressure
  • Non-penetrating deep sclerectomy is performed to provide an alternative route for aqueous fluid drainage and to reduce pressure.
  • Cylindrical tubes such as the AQUAFLOW Collagen Glaucoma Drainage Device (STAAR Surgical Company, Monrovia, CA), are used to maintain the subscleral drainage channel.
  • the AQUAFLOW is 4.0mm long by 0.5mm wide (when dry) and is composed entirely of lyophilized, cross-linked porcine collagen. After placement, the device absorbs fluid and swells to fill the surgically created space to allow ongoing drainage of the aqueous humor. Over time, the device begins to slowly dissolve until it is completely resorbed within 6 - 9 months.
  • Representative examples of glaucoma drainage devices are described in U.S. Patent Nos. 4,722,724, 5,178,604 and 5,893,837. Loading an MMPI into a collagen glaucoma drainage device may be used for slowing the dissolution rate of the implant and prolonging its effectiveness beyond 6 - 9 months.
  • the present invention provides a collagen-containing glaucoma drainage device in combination with a MMPI.
  • a collagen glaucoma drainage device in combination with a MMPI.
  • TIMP-1 tetracycline
  • chemically-modified tetracycline doxycycline
  • minocycline minocycline
  • BATIMISTAT MARIMASTAT
  • RO-1130830 CGS 27023A
  • BMS- 275291 CMT-3
  • SOLIMASTAT ILOMASTAT
  • CP-544439 PRINOMASTAT
  • PNU- 1427690 SU-5402 and TROCADE
  • the effective lifespan of the device can be increased beyond 9 months.
  • 1 - 30%» of TIMP-1, tetracycline, doxycycline, minocycline, BATIMASTAT, MARIMASTAT, RO-1130830, CGS 27023A, BMS-275291, CMT-3, SOLIMASTAT, ILOMASTAT, CP-544439, PRINOMASTAT, PNU-1427690, SU-5402 and/or TROCADE (by weight) is/are loaded into PLGA microspheres, which are in turn loaded into the collagen cylinder, to produce sustained release of the drug over a period of several months.
  • GERD gastroesophageal reflux disease
  • a collagen-bulking agent into the vicinity of the lower esophageal sphincter (LES) can restore the structure of the tissue and reduce backflow into the esophagus.
  • the collagen-bulking agent is typically administered through direct injection under endoscopic vision.
  • the principle problem is degradation of the implant, which limits the longevity of the treatment.
  • a repeat intervention, with either reinjection of collagen or open surgical reinforcement of the sphincter, is required when the collagen loses its structural integrity and can no longer maintain the LES.
  • an MMPI is added to the collagen-based injection in a sustained-release form to decrease the rate of degradation of the LES implant and prolong its activity in vivo beyond that seen with collagen alone (e.g.
  • CMTs chemically-modified tetracyclines
  • BATIMASTAT MARIMASTAT
  • RO- 1130830 RO- 1130830
  • CGS 27023A CGS 27023A
  • BMS-275291 CMT-3
  • SOLIMASTAT ILOMASTAT
  • CP- 544439 PRINOMASTAT
  • PNU-1427690 SU
  • a preferred MARIMASTAT-loaded injectable collagen implant is
  • MARIMASTAT 0.001% -30% MARIMASTAT by weight (i.e., l ⁇ g - 30mg MARIMISTAT per lOOmg of collagen injected).
  • a particularly preferred dosage is 0.01 - 15% MARIMASTAT by weight (i.e., lO ⁇ g - 15mg per lOOmg of collagen implanted). Regardless of the size or type of collagen implant injected, the total drag content should typically not exceed 50mg of MARIMASTAT.
  • 0.001 - 30%) MARIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of MARIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% BATIMASTAT by weight (i.e., l ⁇ g - 30mg BATIMASTAT per lOOmg of collagen injected).
  • a particularly preferred dosage is 0.01 to 30% by weight (lO ⁇ g - 30mg per lOOmg of collagen implanted).
  • the total drug content should typically not exceed 300mg of BATIMASTAT. In one embodiment, 0.01 - 30%
  • BATIMASTAT by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of BATIMASTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Doxycycline-loaded collagen bulking agents for GERD Apreferred composition is 0.001 - 30% doxycycline by weight (l ⁇ g -
  • a particularly preferred dosage is 0.01 - 30% doxcycline by weight (lO ⁇ g - 30mg doxycycline per lOOmg of collagen implanted). Regardless of the size or type of collagen implant employed, the total drag content should typically not exceed 200mg of doxycycline. In one embodiment, 0.001 - 30% doxycycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drug over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or non-crosslinked
  • Pharmaceutically acceptable analogues and derivatives of doxycycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% tetracycline by weight -(l ⁇ g - 30mg tetracycline per lOOmg of collagen injected).
  • a particularly preferred dosage is 0.01 - 30% tetracycline by weight (lO ⁇ g - 30mg tetracycline per lOOmg of collagen implanted). Regardless of the size or type of collagen implant employed, the total drug content should typically not exceed lOOOmg of tetracycline.
  • 0.001 - 30% tetracycline by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drag over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of tetracycline, including chemically-modifed tetracylines (CMTs) are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Minocycline-loaded collagen bulking agents for GERD A preferred composition is 0.001 - 30% minocycline by weight (l ⁇ g -
  • minocycline per lOOmg of collagen injected.
  • a particularly preferred dosage is 0.01 - 6% minocycline by weight (10 ⁇ g - 6 mg minocycline per lOOmg of collagen implanted). Regardless of the size or type of collagen implant employed, the total drug content should typically not exceed 200mg of minocycline.
  • 0.001 - 30% minocycline is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of minocycline are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 - 30% TROCADE by weight (l ⁇ g - 30mg TROCADE per lOOmg of collagen injected).
  • a particularly preferred dosage is
  • TROCADE by weight 0.01 to 5% TROCADE by weight (lO ⁇ g - 5mg TROCADE per lOOmg of collagen implanted). Regardless of the size or type of collagen implant employed, the total drag content should typically not exceed 150mg of TROCADE. In one embodiment, 0.001 -
  • TROCADE by weight is loaded into PLGA microspheres, which are in turn loaded into the collagen implant, to produce sustained release of the drag over a period ranging from several days to several months.
  • Any source of collagen e.g., porcine, bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TROCADE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Collagen-based injectables may also be used in the local management of fecal incontinence.
  • Fecal incontinence is a common and socially disabling condition that affects up to 11% of North American adults. Incontinence to flatus or feces can be caused by a variety if factors, but is more common in women where the anal sphincter can be damaged during child birth (especially those who have suffered a third degree vaginal tear, required forceps, had large babies, and/or experienced long labor as part of a vaginal delivery).
  • sphincter injury obstetric, surgical, accidental
  • anorectal disease hemorrhoids, rectal prolapse, inflammatory bowel disease, fistulas, tumors, colon resection, fecal impaction, diarrhea
  • congenital spina bifida, meningocele, Hirshsprang's disease
  • idiopathic or behavioral (resistance to defecation, dementia, mental retardation).
  • Passive fecal incontinence i.e., occurring without the patient's awareness
  • Passive fecal incontinence is primarily due to dysfunction of the internal anal sphincter, while urge fecal incontinence (the inability to voluntarily suppress defecation) is usually due to external anal sphincter dysfunction.
  • peri-anal-sphincter collagen injections have been used with a great deal of success in the management of fecal incontinence, the majority of cases require more than one treatment due to the limited durability of the collagen implant.
  • Utilizing a MMPI-loaded collagen injection according to the present invention can sustain the activity of the implant and reduce the need for, and frequency of, subsequent peri-anal-sphincter injections.
  • CONTIGEN purified bovine dermal glutaraldehyde crosslinked collagen dispersed in phosphate buffered physiologic saline at 35 mg/ml available through CR Bard
  • Other collagen based injectable products including those derived from non-bovine, human, or recombinant sources can also be utilized in this embodiment;
  • CONTIGEN the crosslinked collagen begins to degrade in approximately 12 weeks and degrades completely within 10 to 19 months.
  • an MMPI is added to the collagen-based injectable in a sustained-release form to decrease the rate of degradation of the implant and prolong its activity in vivo beyond that seen with collagen alone (i.e., consistently greater than 6 months in the majority of patients and beyond 1 year in a significant percentage of others).
  • Peri-anal-sphincter injection of an MMPI-loaded collagen is performed in the following manner. Prior to administration of the material, the patient should have completed two skin tests (conducted 2 weeks apart) to test for an allergic response. If these tests are negative, the MMPI-loaded collagen injection can be administered to the patient. A refrigerated, single use, pre-loaded - syringe with a fine gauge needle containing 2.5 mL of the implant material is used. The patient is placed in the lithotomy position, 10 mL of 2% lidocaine is inserted into the perineal skin or the rectal mucosa depending upon the region of injection selected.
  • the needle is inserted through the skin or the rectal mucosa into the submucosal plane surrounding the anal sphincter.
  • the MMPI-loaded collagen is injected slowly into the site (typically in 3 injections placed circumferentially, trans- sphincterally, entering away from the anal margin and injecting at, or just above, the dentate line) until symmetry is achieved around the anal canal.
  • Methylene blue, or other nontoxic coloring agents can be added to the implant to assist with visualization of the injection.
  • MMPI's such as TIMP-1, tetracycline, doxycycline, minocycline, BATIMISTAT, MARIMISTAT, Ro-1130830, CGS 27023A, BMS-275291, CMT-3, Solimastat, Ilomastat, CP-544439, Prinomastat, PNU-1427690, SU-5402, and TROCADE are particularly preferred.
  • the following compositions are ideally suited for use as anal sphincter bulking agents:
  • a preferred composition is 0.001% -30% MARIMISTAT per cc (i.e., 1 ⁇ g-30 mg MARIMISTAT by weight) of collagen saline suspension.
  • a particularly preferred dosage is 0.01-15% MARIMISTAT (i.e., 10 ⁇ g to 15 mg) per mL of collagen/saline suspension. Therefore, the total dosage delivered in a 2.5 mL treatment would typically not exceed 45 mg (or less than the established well tolerated single daily does of 50 mg).
  • 0.001-30% MARIMISTAT is loaded into PLGA microspheres or other polymer-based microspheres which are in turn loaded into the collagen, in order to produce sustained release of the material over a period ranging from several days to several months.
  • Any source of injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of MARIMISTAT are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001 to 30% BATIMISTAT (i.e., 1 ⁇ g to 30 mg BATIMISTAT by weight) per mL of injectable collagen/saline suspension.
  • a particularly preferred dosage is 0.01 to 30%) (10 ⁇ g to 30 mg by weight) per mL of collagen saline suspension. Therefore, the total dosage delivered in a 2.5 mL treatment would typically not exceed 75 mg of BATIMISTAT (or less than the established well tolerated single dose of 300 mg/m 2 ).
  • 0.001 to 30% BATIMISTAT is loaded into PLGA microspheres or other polymer-based microspheres which are in turn loaded into the collagen, in order to produce sustained release of the agent over a period ranging from several days to several months. Any source of injectable collagen
  • BATIMISTAT e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • a preferred composition is 0.001-30%) doxycycline (1 ⁇ g to 30mg doxycycline by weight) per mL of injectable collagen/saline suspension.
  • a particularly preferred dosage is 0.01 to 30% doxcycline (10 ⁇ g to 30 mg doxycycline by weight) per mL of collagen/saline suspension. Therefore the total dosage administered in a 2.5 mL treatment would typically not exceed 75 mg (or less than the well tolerated daily dosage of 100 mg).
  • 0.001%) to 30% doxycycline is loaded into PLGA microspheres or other polymer-based microspheres which are in turn loaded into the collagen, in order to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of DOXYCYCLINE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001-30%) tetracycline (1 ⁇ g to 30 mg tetracycline by weight) per mL of injectable collagen/saline suspension.
  • a particularly preferred dosage is 0.01 to 30%> tetracycline (10 ⁇ g to 30 mg tetracycline by weight) per mL of collagen/saline suspension. Therefore the total dosage administered in a 2.5 mL treatment would typically not exceed 75 mg (or less than the well tolerated daily dosage of 1 g).
  • 0.001%> to 30%> tetracycline is loaded into PLGA microspheres or other polymer-based microspheres which are in turn loaded into the collagen, in order to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TETRACYCLINE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001-30%) minocycline (1 ⁇ g -to- 30 mg tetracycline by weight) per mL of injectable collagen/saline suspension.
  • a particularly preferred dosage is 0.01 to 6% minocycline (10 ⁇ g to 6 mg minocycline by weight) per cc of collagen saline suspension. Therefore the total dosage administered in a 30 cc treatment would typically not exceed 180 mg or less than the well tolerated daily dosage of 200 mg).
  • 0.001% to 30%> minocycline is loaded into PLGA microspheres or other polymer-based microspheres which are in turn loaded into the collagen, in order to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of MINOCYCLINE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • a preferred composition is 0.001-30% TROCADE (1 ug to 30 mg TROCADE by weight) per mL of injectable collagen/saline suspension.
  • a particularly preferred dosage is 0.01 to 5% TROCADE (10 ⁇ g to 5 mg TROCADE by weight) per ml of collagen/saline suspension. Therefore the total dosage administered in a 2.5 mL treatment would typically not exceed 75 mg.
  • 0.001% to 30% TROCADE is loaded into PLGA microspheres or other polymer-based microspheres which are in turn loaded into the collagen, in order to produce sustained release of the agent over a period ranging from several days to several months.
  • Any source of injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • injectable collagen e.g., bovine, human, or recombinant; crosslinked or noncrosslinked
  • Pharmaceutically acceptable analogues and derivatives of TROCADE are also suitable for use in this embodiment either alone or in combination with other MMPIs.
  • Collagen Source Skin is removed from freshly sacrifice rabbits. The removed skin is shaved, defatted by sharp dissection and cut into two cm squares. The skm squares are freeze-dried at ambient temperature for 24 hours and then ground, with the aid of solid CO 2 , in a mill to produce a powder.
  • Solubilization A suspension of the powdered skin in prepared by adding the powdered material to a 0.5 M acetic acid solution such that the skin concentration is 5 g dry wt skin/1. The suspension is cooled to 10°C. A freshly prepared pepsin solution (0.5 g in 10 ml 0.01 N HC1) is added to the skin suspension and the mixture was incubated for 5 days at 10°C with occasional stirring.
  • the remaining pepsin in the mixture was denatured by adding 5 ml Tris base and adjusting the pH to 7.0 with 3 N NaOH at 4°C. 30 g NaCl is stirred into the mixture to keep the collagen in solution. After 4 hours, the mixture is centrifuged at 30,000 g for 30 minutes to remove the precipitated pepsin.
  • the enzymatically treated collagen is precipitated from the supernatant liquid by adding an additional 140 g NaCl.
  • the solution is stirred and allowed to stand for 4 hours at 4°C.
  • the precipitated collagen is centrifuged out at 30,000 g for 30 minutes.
  • the resulting collagen pellet is resuspended in 200 ml deionized water. 0.5 N acetic acid is added to bring the final volume to one liter.
  • the collagen is precipitated from this solution by adding 50 g NaCl, allowing the solution to stand for 5 hours at 4°C and centrifuging at 30,000 g for 30 minutes.
  • the collagen pellet is resuspended in 200 ml distilled water, transferred into sterilized dialysis tubing and dialysed for 72 hours against 50 volumes 1 N acetic acid.
  • the collagen was then dialysed for 24 hours against 50 volumes 0.001 N acetic acid with the solution being changed 3 times during this period.
  • the dialysed solution is then concentrated by placing the dialysis tube on sterile absorbant towels in a laminar-flow bacteriologic barrier until the concentration reached 12-15 mg collagen/ml solution.
  • the concentrated solution is then dialysed against 50 volumes 0.001 N acetic acid for 24 hours.
  • the collagen solution is then stored in sterile vials at 4°C.
  • a buffered salt solution (NaCl 2.5 n ⁇ M/1, NaHP0 0.1 mM/1, pH 7.4) is added at 4°C to the collagen solution in a volume: volume ratio of 10:1 (collagembuffer), and the buffered concentrate is transferred to a chilled (4°C) syringe.
  • the buffered salt solution can also contain 0.3-1% (w/v) of a local anesthetic (e.g., Lidocaine).
  • PBS phosphate buffered saline
  • TIMP-1 concentration typically from 1 to 10 mg/niL
  • the solvent is then slowly removed via evaporation and the microspheres collected by centrifugation.
  • the particles are washed (5 times) with deionized water and then frozen in a dry ice/acetone bath and lyophilized overnight to yield a white freely flowing powder of microspheres.
  • the method described above is also used to prepare microspheres containing TIMP-2, TIMP-3 and TIMP-4.
  • PVA solution is transferred into a 400ml beaker.
  • the beaker is secured to the stand using double-sided adhesive tape.
  • a 3 -blade stirring rod blade is placed into the beaker and adjusted to a height of approx. 0.5 cm above the beakerbottom.
  • the stirrer motor (DYNA-MIX from Fisher Scientific) is turned on to 2.5 at first.
  • the 10ml PLGA/BATIMASTAT solution is poured into the PVA solution during agitation.
  • the stirring speed is the gradually increased to a setting of 5.
  • the stirring is continued for 2.5 to 3.0 hours.
  • microspheres were filtered through a 2 metal sieves (53 ⁇ m (top) and 25 ⁇ m (bottom)) into a 100ml beaker in order to remove any large sized material.
  • the microspheres are washed with distilled water while filtering.
  • the microspheres that are collected in the filtrate were centrifuged (lOOOrpm, lOmin.) to sediment the microspheres.
  • the supernatant is removed using a pasteur pipette and the pellet is re-suspended with 100ml distilled water. This process is repeated 2 additional times. — -
  • the washed microspheres are transferred into a glass container.
  • the transfer is completed by rinsing the beaker with a small amount of distilled water (20- 30ml).
  • the container is sealed with Parafilm and placed into a -20°C freezer over night.
  • the frozen microsphere solution is then freeze-dried using a freeze-drier for about 3 days.
  • the dried microspheres are transferred into 20ml scintillation vial and were stored at -20°C.
  • the microspheres are then terminally sterilized by irradiation with at least 2.5 Mrad Cobalt-60 (Co-60) x-rays.
  • EXAMPLE 7 PREPARATION OF MARMISTAT-LOADED MICROSPHERES USING AN OIL-IN- WATER
  • METHOD MARIMASTAT-loaded microspheres are prepared in a similar manner to that described in the example above, except that MARIMASTAT is used instead of BATIMASTAT.
  • TROCADE-loaded microspheres are prepared in a similar manner to that described in the example above, except that TROCADE is used instead of Batimistat.
  • Polymer is synthesized using DL-lactide and methoxy poly (ethylene glycol) [MePEG 2000] in presence of 0.5% w/w stannous octoate through a bulk ring opening polymerization.
  • Reaction glassware is washed and rinsed with Sterile Water for Irrigation USP, dried at 37°C, followed by depyrogenation at 250°C for at least 1 hour.
  • MePEG 2000 and DL-lactide are weighed (240 g and 160 g, respectively) and transferred to a round bottom flask using a stainless steel funnel.
  • a 2-inch Teflon® coated magnetic stir bar is added to the flask.
  • a glass stopper is used to seal the flask, which is then immersed, up to the neck, in a pre-heated oil bath. The oil bath is maintained at 140°C using a temperature controlled hotplate.
  • micellar Batimistat (Batimistat/polymer matrix)
  • Reaction glassware is washed and rinsed with Sterile Water for Irrigation USP, dried at 37°C, followed by depyrogenation at 250°C for at least 1 hour.
  • a phosphate buffer, 0.08M, pH 7.6 is prepared.
  • the buffer is dispensed at the volume of 1 mL per vial.
  • the vials are heated for 2 hours at 90°C to dry the buffer.
  • the temperature is then raised to 160°C and the vials are dried for an additional 3 hours.
  • the polymer is dissolved in THF at 10%) w/v concentration with stirring and heat.
  • the polymer solution is then centrifuged at 3000 rpm for 30 minutes.
  • the supernatant is poured off and set aside.
  • Additional THF is added to the precipitate and centrifuged a second time at 3000 rpm for 30 minutes.
  • the second supernatant is pooled with the first supernatant.
  • BATIMASTAT is weighed and then added to the supernatant pool.
  • the solution is brought to the final desired volume with THF to make a 9.9%) polymer solution containing 1.1% BATIMASTAT.
  • micellar Batimistat is dispensed into the vials containing dried phosphate buffer at a volume of 1 mL per vial.
  • the vials are placed in a vacuum oven at 50°C.
  • the vacuum is set at ⁇ - 80kPa and the vials remain in the oven overnight (15 to 24 hours).
  • the vials are stoppered with Teflon faced gray butyl stoppers and sealed with aluminum seals.
  • the BATIMASTAT/polymer matrix is sterilized using 2.5 Mrad ⁇ -ray irradiation.
  • Each vial contains approximately 11 mg BATIMASTAT, 99 mg polymer, and 11 mg phosphate salts.
  • the vials are stored at 2° to 8°C until constitution.
  • sterile biological safety cabinet two milliliters sterile saline is added to a vial that contained approximately 11 mg BATIMASTAT, 99 mg polymer, and 11 mg phosphate salts (as prepared above).
  • the contents of the vial are dissolved in 2 mL sterile saline by placing the vial in a water bath at 37 °C for approx. 30 minutes with periodic vortexing.
  • a sterile 1 mL syringe a 1 mL aliquot of the micellar BATIMASTAT solution is withdrawn from the vial and was injected into 29 mL collagen gel.
  • the sample is mixed to produce a homogeneous solution of the micellar BATIMASTAT in the collagen gel.
  • the sample is then loaded into lmL syringes for use in the in vivo experiments.
  • the liquid composition is transferred to a stainless steel pan and placed in a forced air oven at 50°C for about 48 hours to remove residual solvent.
  • the composition is then cooled to ambient temperature and is allowed to solidify to form Batimistat-polymer matrix.
  • a phosphate buffer is prepared by combining 237.8 g of dibasic sodium phosphate heptahydrate, 15.18 g of monobasic sodium phosphate monohydrate in 1600 ml of water.
  • 327 g of the BATIMASTAT-polymer matrix is added and stirred for 2 hours to dissolve the solids. After a clear solution is achieved, the volume is adjusted to 2000 ml with additional water. Vials are filled with 15 ml aliquots of this solution and freeze dried by cooling to -34°C, holding for 5 hours, heating to -16°C while reducing pressure to less than 0.2 mm Hg, holding for 68 hours, heating to 30°C while maintaining low pressure, followed by holding for a further 20 hours. The result is a freeze-dried matrix that could constituted to form a clear micellar solution.
  • micellar BATIMASTAT material 40 mg is weighed into a capped 1 mL syringe.
  • the plunger is replaced and the syringe is sealed in a plastic pouch using a heat sealer.
  • the sample is sterilized using 2.5 Mrad ⁇ -ray irradiation.
  • the plastic pouch containing the sterilized freeze- dried material is opened and connected to a dual syringe connector.
  • a syringe containing 2mL 3.5%> bovine collagen (95% type I and 5% Type III) is attached to the remaining end of the dual syringe connector.
  • the plunger of the syringe containing the collagen material is pushed in order to transfer the collagen material into the syringe containing the micellar material.
  • the material is passed rapidly from one syringe to the other until a homogeneous solution is obtained.
  • the material is then transferred into the syringe that originally contained the collagen. This syringe is disconnected from the connector and a 30-gauge needle is connected to the syringe. The material is now ready for application.
  • 40mg of the freeze-dried microsphere BATIMASTAT material is weighed into a capped 1 mL syringe.
  • the plunger is replaced and the syringe is sealed in a plastic pouch using a heat sealer.
  • the sample is sterilized using 2.5 Mrad ⁇ -ray irradiation.
  • the plastic pouch containing the sterilized-freeze- dried material is opened and connected to a dual syringe connector.
  • a syringe containing 2mL 3.5% bovine collagen (95% type I and 5% Type III) is attached to the remaining end of the dual syringe connector.
  • the plunger of the syringe containing the collagen material is pushed in order to transfer the collagen material into the syringe containing the micellar material.
  • the material is passed from one syringe to the other until a homogeneous solution is obtained.
  • the material is then transferred into the syringe that originally contained the collagen. This syringe is disconnected from the connector and a 30-gauge needle is connected to the syringe. The material is now ready for application.
  • a total of 100 mg of egg phosphatidylcholine (Avanti Polar Lipids, Alabaster, AL) and cholesterol (Sigma Chemical Co., St. Louis, MO) [5:1 molar ratio] are added to 5 mL dichloromethane in a 50 mL round bottom flask. Once dissolved, 3 mg BATIMASTAT is added to the solution. The solvent is removed under slight vacuum using the rotary evaporator. The lipid-drag mixture is dried overnight under vacuum. 5 mL 0.9% NaCl solution is added to the dried lipid-drag mixture. The solution is gently rotated for 1 hour using a rotary evaporator and a water bath setting of 37°C.
  • the samples When 5% maltose is added to the 0.9% NaCl constitution solution, the samples are frozen in acetone dry ice and are freeze-dried to produce a solid product.
  • a certain amount of the freeze- dried microsphere BATIMISTAT material (prepared as described above) is weighed into a capped 1 mL syringe. The plunger is replaced and the syringe is sealed in a plastic pouch using a heat sealer. The sample is sterilized using 2.5 Mrad ⁇ -ray irradiation.
  • the plastic pouch containing the sterilized freeze-dried material is opened and connected to a dual syringe connector.
  • a syringe containing 3.5% bovine collagen (95% type I and 5% Type III) is attached to the remaining end of the dual syringe connector.
  • the plunger of the syringe containing the collagen material is pushed in order to-transfer the collagen material into the syringe containing the micellar material.
  • the material is passed from one syringe to the other until a homogeneous solution is obtained.
  • the material is then transferred into the syringe that originally contained the collagen. This syringe is disconnected from the connector and a 30-gauge needle is connected to the syringe. The material is now ready for application.
  • SUV Liposomes 3.5% bovine collagen (95% type I and 5% Type III)
  • the liposomes prepared above are size reduced by placing the sample in an ultrasonic bath (45 °C) for 10 minutes.
  • the solution changed from a opaque - milky solution to a transparent solution with a blue tinge.
  • This solution is either used as is or is freeze-dried to produce a solid product.
  • the solid product can be used to prepare a collagen solution in a similar manner to that described above.
  • the liposomes prepared above are size reduced by placing the sample in an ultrasonic bath (45°C) for 10 minutes.
  • the solution changed from a opaque - milky solution to a transparent solution with a blue tinge.
  • This solution is either used as is or is freeze-dried to produce a solid product.
  • the solid product can be used to prepare a collagen solution in a similar manner to that described above.
  • Collagen is the only protein containing 3- and 4-hydroxyproline and thus the effect of a drag formulation on collagen -degradation can be quantified by the measurement of hydroxyproline following treatment with a drug-loaded formulation at various time points.
  • Human dermal fibroblasts are grown in culture media for 3 weeks in the presence of vitamin C to form a three dimensional collagen matrix.
  • Various concentrations of drug formulations can be aliquoted onto the collagen matrix along with various concentrations of collagen degrading enzymes. The duration of drug incubation can be altered.
  • Cell supematants are collected in 0.1 M NaCl, 5 mM NaHCO 3 and hydrolyzed in 6N HC1 for 16 hours at 110°C.
  • Stock buffer consists of a 1 L solution containing 50 g of citric acid, 12 mL of glacial acetic acid, 120 g of sodium acetate and 34 g of NaOH.
  • Each sample is tested in triplicate by aliquoting 100 ⁇ L of the sample in a 96-well plate with 50 ⁇ L of Chloramine-T reagent (1.41 g of Chloramine-T dissolved 20.7 mL of H 2 O, 26 mL of n-propanol, and stock buffer) and 50 ⁇ L of dimethylaminobenzaldehyde reagent (15 g of p-dimethylaminobenzaldehyde in 60 mL of n-propanol and 26 mL of 60% perchloric acid added slowly). The plate is incubated at 60°C for 15 minutes and placed at 8-10°C for 5 minutes.
  • Optical density is read immediately on microplate spectrophotometer at 550 nm absorbance. Absorbance over triplicate wells is averaged after subtracting background and concentration values are obtained from the hydroxyproline standard curve (0-5 ⁇ g). The amount of hydroxyproline measured is a determination of collagen degradation. A reduction in the amount of hydroxyproline following incubation with a drag formulation indicates a reduction in the degradation of collagen.
PCT/US2003/041330 2002-12-27 2003-12-24 Compositions and methods of using collagen and mmpi WO2004060425A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2003300379A AU2003300379A1 (en) 2002-12-27 2003-12-24 Compositions and methods of using collagen and MMPI
CA002509060A CA2509060A1 (en) 2002-12-27 2003-12-24 Compositions and methods of using collagen and mmpi
JP2004565732A JP2006516252A (ja) 2002-12-27 2003-12-24 コラーゲンおよびｍｍｐｉを用いる組成物および方法
BR0317715-7A BR0317715A (pt) 2002-12-27 2003-12-24 Composições e processos de uso de collajolie
EP03814968A EP1585555A2 (en) 2002-12-27 2003-12-24 Compositions and methods of using collagen and mmpi

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43680602P 2002-12-27 2002-12-27
US60/436,806 2002-12-27

Publications (2)

Publication Number Publication Date
WO2004060425A2 true WO2004060425A2 (en) 2004-07-22
WO2004060425A3 WO2004060425A3 (en) 2005-01-06

Family

ID=32713092

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/041330 WO2004060425A2 (en) 2002-12-27 2003-12-24 Compositions and methods of using collagen and mmpi

Country Status (9)

Country Link
US (1) US20040192658A1 (pt)
EP (1) EP1585555A2 (pt)
JP (1) JP2006516252A (pt)
KR (1) KR20050086949A (pt)
CN (1) CN1732023A (pt)
AU (1) AU2003300379A1 (pt)
BR (1) BR0317715A (pt)
CA (1) CA2509060A1 (pt)
WO (1) WO2004060425A2 (pt)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082431A1 (en) * 2004-02-23 2005-09-09 Kensey Nash Corporation Gel suitable for implantation and delivery system
WO2006069741A2 (de) * 2004-12-23 2006-07-06 Ossacur Ag Gelartiges material zur füllung von knochen- und/oder knorpeldefekten
DE102006026589A1 (de) * 2006-06-01 2007-12-06 Ossacur Ag Verwendung eines Kollagens mit osteoinduktiven Wirkstoffen zur Behandlung von Sehnen- und/oder Bänderdefekten
JP2008538367A (ja) * 2005-04-18 2008-10-23 ブラッコ・リサーチ・ソシエテ・アノニム 超音波媒介デリバリー用ガス充填マイクロカプセル含有医薬組成物
WO2010029352A1 (en) * 2008-09-09 2010-03-18 University Of East Anglia Treatment of fibrotic eye disorders using an mmp2 inhibitor
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
WO2012094708A1 (en) * 2011-01-12 2012-07-19 The University Of Queensland Bone graft biomaterial
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US8888811B2 (en) 2008-10-20 2014-11-18 Covidien Lp Device and method for attaching an implant to biological tissue
US8906045B2 (en) 2009-08-17 2014-12-09 Covidien Lp Articulating patch deployment device and method of use
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
US9089326B2 (en) 2011-10-07 2015-07-28 Ethicon Endo-Surgery, Inc. Dual staple cartridge for surgical stapler
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
US9999408B2 (en) 2011-09-14 2018-06-19 Ethicon Endo-Surgery, Inc. Surgical instrument with fluid fillable buttress
US9999424B2 (en) 2009-08-17 2018-06-19 Covidien Lp Means and method for reversibly connecting an implant to a deployment device
US10159554B2 (en) 2008-02-18 2018-12-25 Covidien Lp Clip for implant deployment device
US10182898B2 (en) 2008-02-18 2019-01-22 Covidien Lp Clip for implant deployment device
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
US10617744B2 (en) 2015-06-15 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
EP2797953B1 (en) * 2011-12-28 2020-06-03 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US10688154B2 (en) 2011-04-08 2020-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US10688130B2 (en) 2013-12-09 2020-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
US11236340B2 (en) 2010-01-28 2022-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060002969A1 (en) * 2004-01-27 2006-01-05 University Of Washington Methods for reducing the foreign body reaction
US7597687B2 (en) 2004-10-29 2009-10-06 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8206448B2 (en) 2004-10-29 2012-06-26 Spinal Restoration, Inc. Injection of fibrin sealant using reconstituted components in spinal applications
US8419722B2 (en) * 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
US20060073208A1 (en) * 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US8828977B2 (en) * 2006-02-16 2014-09-09 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
US20080177330A1 (en) * 2006-10-24 2008-07-24 Ralph James D Self-locking screws for medical implants
US20120195938A1 (en) * 2007-05-30 2012-08-02 James Louis Rutkowski Formulations and methods for recovery from dental surgery
US20090054984A1 (en) 2007-08-20 2009-02-26 Histogenics Corporation Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects
US9301826B2 (en) 2008-02-18 2016-04-05 Covidien Lp Lock bar spring and clip for implant deployment device
CA2721507C (en) 2008-04-18 2017-10-03 Collplant Ltd. Methods of generating and using procollagen
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US8039433B2 (en) 2008-08-19 2011-10-18 Warsaw Orthopedic, Inc. Osteogenic compositions containing a coloring agent
US8252228B1 (en) * 2008-10-13 2012-08-28 Abbott Cardiovascular Systems Inc. Methods for sterilizing carriers for treatment of a kidney
US20100094338A1 (en) * 2008-10-15 2010-04-15 Tyco Healthcare Group Lp Hydroxamate-initiated polymers
ES2630102T3 (es) * 2011-04-26 2017-08-18 Rdd Pharma Ltd. Oximetazolina para el tratamiento de trastornos ano-rectales
US8998059B2 (en) 2011-08-01 2015-04-07 Ethicon Endo-Surgery, Inc. Adjunct therapy device having driver with cavity for hemostatic agent
US9492170B2 (en) 2011-08-10 2016-11-15 Ethicon Endo-Surgery, Inc. Device for applying adjunct in endoscopic procedure
US8998060B2 (en) 2011-09-13 2015-04-07 Ethicon Endo-Surgery, Inc. Resistive heated surgical staple cartridge with phase change sealant
US9101359B2 (en) 2011-09-13 2015-08-11 Ethicon Endo-Surgery, Inc. Surgical staple cartridge with self-dispensing staple buttress
US9254180B2 (en) 2011-09-15 2016-02-09 Ethicon Endo-Surgery, Inc. Surgical instrument with staple reinforcement clip
US9125649B2 (en) 2011-09-15 2015-09-08 Ethicon Endo-Surgery, Inc. Surgical instrument with filled staple
US9198644B2 (en) 2011-09-22 2015-12-01 Ethicon Endo-Surgery, Inc. Anvil cartridge for surgical fastening device
US9393018B2 (en) 2011-09-22 2016-07-19 Ethicon Endo-Surgery, Inc. Surgical staple assembly with hemostatic feature
US8985429B2 (en) 2011-09-23 2015-03-24 Ethicon Endo-Surgery, Inc. Surgical stapling device with adjunct material application feature
US8899464B2 (en) 2011-10-03 2014-12-02 Ethicon Endo-Surgery, Inc. Attachment of surgical staple buttress to cartridge
EP2814517A1 (en) * 2012-02-15 2014-12-24 Microarray Limited Wound screen
TWI478943B (zh) * 2012-12-27 2015-04-01 Ind Tech Res Inst 高分子組成物用於製備具有抑制基質金屬蛋白酶之活性的功效的醫療器材或抑制劑的用途
US10052400B2 (en) 2014-05-30 2018-08-21 Sofradim Production Method for preparing neutralized matrix of non-antigenic collagenous material
CN105012995B (zh) * 2015-06-04 2018-03-09 武汉维斯第医用科技股份有限公司 一种含促骨愈合药物的胶原蛋白海绵及其制备方法
CN107811965A (zh) * 2017-04-25 2018-03-20 中国药科大学 一种缓释巴马司他的聚酯－聚醚温敏凝胶制剂及制备方法
TW201932124A (zh) * 2018-01-18 2019-08-16 近鎰生技股份有限公司 止血材料、其製備方法及包含其的藥物組合物

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1068587A (en) * 1963-12-06 1967-05-10 Biorex Laboratories Ltd Dental fillers and bone cements comprising collagen
WO1989004646A1 (en) * 1987-11-13 1989-06-01 Jefferies Steven R Bone repair material and delayed drug delivery
US5073114A (en) * 1988-02-23 1991-12-17 Detsch Steven G Bone growing method and composition
WO1996039202A1 (en) * 1995-06-06 1996-12-12 Osteogenics Inc. Biocompatible hydroxyapatite formulations and uses therefor
WO1998022153A1 (en) * 1996-11-15 1998-05-28 The Lions Eye Institute Of Western Australia Incorporated Cross-linking of collagen in situ and uses thereof in wound healing
WO1999045972A2 (en) * 1998-03-09 1999-09-16 Stichting Voor De Technische Wetenschappen Skin substitute and a topical composition for skin wounds
WO2003059296A2 (en) * 2001-12-28 2003-07-24 Angiotech International Ag. Compositions comprising collagen and metalloprotease inhibitors

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862225A (en) * 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US4066694A (en) * 1971-02-09 1978-01-03 Pfizer Inc. 4-hydroxy-4-dedimethylamino-tetracyclines
BE792050A (fr) * 1971-12-04 1973-03-16 Amezua Fernandez Piedal Procede d'obtention d'un nouveau derive antibiotique
US3951962A (en) * 1973-11-14 1976-04-20 Yamanouchi Pharmaceutical Co., Ltd. Novel N-alkenyltetracycline derivatives
US3949073A (en) * 1974-11-18 1976-04-06 The Board Of Trustees Of Leland Stanford Junior University Process for augmenting connective mammalian tissue with in situ polymerizable native collagen solution
CA1073360A (en) * 1975-10-22 1980-03-11 John R. Daniels Non-antigenic collagen and articles of manufacture
US4018889A (en) * 1976-01-02 1977-04-19 Pfizer Inc. Oxytetracycline compositions
US4193813A (en) * 1976-09-07 1980-03-18 Medi-Coll, Inc. Method for making collagen sponge
US4263293A (en) * 1980-05-30 1981-04-21 E. R. Squibb & Sons, Inc. Heterocyclic containing amides as inhibitors of mammalian collagenase
US4367233A (en) * 1981-10-02 1983-01-04 American Home Products Corporation Inhibitors of mammalian collagenase
US4374765A (en) * 1981-10-07 1983-02-22 American Home Products Corporation Mammalian collagenase inhibitors
US4371466A (en) * 1981-10-07 1983-02-01 American Home Products Corporation Mammalian collagenase inhibitors
US4371465A (en) * 1981-10-07 1983-02-01 American Home Products Corporation Mammalian collagenase inhibitors
US4424208A (en) * 1982-01-11 1984-01-03 Collagen Corporation Collagen implant material and method for augmenting soft tissue
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4642117A (en) * 1985-03-22 1987-02-10 Collagen Corporation Mechanically sheared collagen implant material and method
CA1260391A (en) * 1985-03-28 1989-09-26 Karl A. Piez Xenogeneic collagen/mineral preparations in bone repair
US4720486A (en) * 1985-10-18 1988-01-19 Monsanto Company Method of inhibiting vertebrate collagenase activity using peptide hydroxamic acid derivatives
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
US5843445A (en) * 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
HU200917B (en) * 1987-07-20 1990-09-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical compositions comprising quinoline or naphthyridinecarboxylic acid and tetracycline derivatives as active ingredient
US4918208A (en) * 1987-07-28 1990-04-17 Nippon Kayaku Kabushiki Kaisha Process for producing 7-dimethylamino-6-demethyl-6-deoxytetracycline
US5290552A (en) * 1988-05-02 1994-03-01 Matrix Pharmaceutical, Inc./Project Hear Surgical adhesive material
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5304595A (en) * 1988-11-21 1994-04-19 Collagen Corporation Collagen-polymer conjugates
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
DE69033982T2 (de) * 1989-03-21 2002-10-24 Us Health Matrizenmetalloproteinase-inhibitor-peptide
US5106949A (en) * 1989-09-15 1992-04-21 Organogenesis, Inc. Collagen compositions and methods for preparation thereof
US5104660A (en) * 1989-11-21 1992-04-14 Bruce A. Barber Method of preparing an antimicrobial wound dressing
US5178604A (en) * 1990-05-31 1993-01-12 Iovision, Inc. Glaucoma implant
US5081106A (en) * 1990-07-16 1992-01-14 The Oregon Health Sciences University Wound dressing protocol utilizing collagen gelatin formed with iodine
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
JPH05503720A (ja) * 1990-12-03 1993-06-17 セルテック　リミテッド ペプチジル誘導体
US5889058A (en) * 1990-12-03 1999-03-30 Celltech Limited Peptidyl derivatives
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
AU654857B2 (en) * 1991-03-29 1994-11-24 Collagen Corporation Device and method for treating facial lines
US5083522A (en) * 1991-05-13 1992-01-28 Ashrow David P Swimming harness
US5281628A (en) * 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5290217A (en) * 1991-10-10 1994-03-01 Earl K. Sipes Method and apparatus for hernia repair
WO1993021942A2 (en) * 1992-05-01 1993-11-11 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
WO1993023075A1 (en) * 1992-05-14 1993-11-25 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
US5594006A (en) * 1993-03-18 1997-01-14 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives as matrix metalloproteinases inhibitors
JP3377856B2 (ja) * 1993-03-25 2003-02-17 イスクラ産業株式会社 骨吸収抑制・骨形成促進化合物
ATE182137T1 (de) * 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
US6013792A (en) * 1993-08-05 2000-01-11 Syntex (U.S.A.), Inc. Matrix metalloprotease inhibitors
US5523291A (en) * 1993-09-07 1996-06-04 Datascope Investment Corp. Injectable compositions for soft tissue augmentation
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
ES2144819T3 (es) * 1994-01-20 2000-06-16 British Biotech Pharm L-terc-leucina-2-piridilamida.
GB9401129D0 (en) * 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
JP3827324B2 (ja) * 1994-01-22 2006-09-27 ブリテッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
EP0763012B1 (en) * 1994-05-28 1999-06-09 British Biotech Pharmaceuticals Limited Succinyl hydroxamic acid, n-formyl-n-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
DE69511089T2 (de) * 1994-06-22 1999-12-16 British Biotech Pharm Metalloproteinase-inhibitoren
US5616689A (en) * 1994-07-13 1997-04-01 Collagen Corporation Method of controlling structure stability of collagen fibers produced form solutions or dispersions treated with sodium hydroxide for infectious agent deactivation
CZ288436B6 (en) * 1994-10-05 2001-06-13 Darwin Discovery Ltd Peptidyl derivatives, their therapeutic use as inhibitors of metalloproteinases and pharmaceutical preparation in which they are comprised
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9423914D0 (en) * 1994-11-26 1995-01-11 British Biotech Pharm Polyether derivatives as metalloproteinase inhibitors
US5843925A (en) * 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
JP2902318B2 (ja) * 1994-12-28 1999-06-07 呉羽化学工業株式会社 エスクレチン誘導体、その製造方法及びマトリックスメタロプロテアーゼ阻害剤
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
DE69627166T2 (de) * 1995-09-11 2004-03-04 Syngenta Participations Ag Verfahren zur herstellung von 2-chlor-5-chlomethyl-thiazol-derivaten
JP4193917B2 (ja) * 1995-12-18 2008-12-10 アンジオデバイス インターナショナル ゲーエムベーハー 架橋ポリマー組成物およびその使用方法
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5863915A (en) * 1996-05-15 1999-01-26 Bayer Corporation Substituted 4-arylbutyric acid derivatives as matrix metalloprotease
ATE233552T1 (de) * 1996-07-22 2003-03-15 Monsanto Co Thiol-sulfonen als metalloproteinaseinhibitoren
US6020366A (en) * 1996-08-16 2000-02-01 Warner-Lambert Company Butyric acid matrix metalloproteinase inhibitors
US6022948A (en) * 1996-09-17 2000-02-08 Washington University Method of cell surface activation and inhibition
US5962481A (en) * 1996-10-16 1999-10-05 American Cyanamid Company Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6228869B1 (en) * 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
GB9621814D0 (en) * 1996-10-19 1996-12-11 British Biotech Pharm Metalloproteinase inhibitors
AU720615B2 (en) * 1997-01-17 2000-06-08 Pharmacia & Upjohn Company Bis-sulfonomides hydroxamic acids as MMP inhibitors
GB9702088D0 (en) * 1997-01-31 1997-03-19 Pharmacia & Upjohn Spa Matrix metalloproteinase inhibitors
US6172057B1 (en) * 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6197791B1 (en) * 1997-02-27 2001-03-06 American Cyanamid Company N-hdroxy-2-(alkyl, aryl, or heteroaryl, sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US5893837A (en) * 1997-02-28 1999-04-13 Staar Surgical Company, Inc. Glaucoma drain implanting device and method
US6169103B1 (en) * 1998-03-03 2001-01-02 Warner-Lambert Fluorine-substituted biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6037361A (en) * 1998-03-09 2000-03-14 Warner-Lambert Company Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases
US6168807B1 (en) * 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6183496B1 (en) * 1998-11-02 2001-02-06 Datascope Investment Corp. Collapsible hemostatic plug
US6511993B1 (en) * 1999-06-03 2003-01-28 Kevin Neil Dack Metalloprotease inhibitors
US6294694B1 (en) * 1999-06-04 2001-09-25 Wisconsin Alumni Research Foundation Matrix metalloproteinase inhibitors and method of using same
US6503892B2 (en) * 2000-04-26 2003-01-07 New England Medical Center Hospitals Inc. Method of using matrix metalloproteinase inhibitors in filtering blebs following glaucoma filtering surgery and in the treatment of ischemic damage to the retina and optic nerve
ATE277938T1 (de) * 2000-07-18 2004-10-15 Leo Pharma As Matrix metalloproteinase inhibitoren

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1068587A (en) * 1963-12-06 1967-05-10 Biorex Laboratories Ltd Dental fillers and bone cements comprising collagen
WO1989004646A1 (en) * 1987-11-13 1989-06-01 Jefferies Steven R Bone repair material and delayed drug delivery
US5073114A (en) * 1988-02-23 1991-12-17 Detsch Steven G Bone growing method and composition
WO1996039202A1 (en) * 1995-06-06 1996-12-12 Osteogenics Inc. Biocompatible hydroxyapatite formulations and uses therefor
WO1998022153A1 (en) * 1996-11-15 1998-05-28 The Lions Eye Institute Of Western Australia Incorporated Cross-linking of collagen in situ and uses thereof in wound healing
WO1999045972A2 (en) * 1998-03-09 1999-09-16 Stichting Voor De Technische Wetenschappen Skin substitute and a topical composition for skin wounds
WO2003059296A2 (en) * 2001-12-28 2003-07-24 Angiotech International Ag. Compositions comprising collagen and metalloprotease inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SUGIYAMA, YUICHI ET AL: "Development of new synthetic bone implant material: trial production of hydroxyapatite - collagen immobilized tetracycline complex" BULLETIN OF KANAGAWA DENTAL COLLEGE , 19(2), 113-16 CODEN: BKDCD5; ISSN: 0385-1443, 1991, XP009032394 *
SUOMALAINEN K ET AL: "TETRACYCLINE INHIBITION IDENTIFIES THE CELLULAR SOURCES OF COLLAGENASE IN GINGIVAL CREVICULAR FLUID IN DIFFERENT FORMS OF PERIODONTAL DISEASES" DRUGS UNDER EXPERIMENTAL AND CLINICAL RESEARCH, BIOSCIENCE EDIPRINT INC, XX, vol. 18, no. 3, 1992, pages 99-104, XP001070805 ISSN: 0378-6501 *

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713303B2 (en) 2002-09-18 2010-05-11 Warsaw Orthopedic, Inc. Collagen-based materials and methods for augmenting intervertebral discs
US7744651B2 (en) 2002-09-18 2010-06-29 Warsaw Orthopedic, Inc Compositions and methods for treating intervertebral discs with collagen-based materials
US7731981B2 (en) 2002-11-15 2010-06-08 Warsaw Orthopedic, Inc. Collagen-based materials and methods for treating synovial joints
WO2005082431A1 (en) * 2004-02-23 2005-09-09 Kensey Nash Corporation Gel suitable for implantation and delivery system
US8551514B2 (en) 2004-02-23 2013-10-08 Kensey Nash Bvf Technology Llc Gel suitable for implantation and delivery system
WO2006069741A2 (de) * 2004-12-23 2006-07-06 Ossacur Ag Gelartiges material zur füllung von knochen- und/oder knorpeldefekten
WO2006069741A3 (de) * 2004-12-23 2006-10-12 Ossacur Ag Gelartiges material zur füllung von knochen- und/oder knorpeldefekten
JP2008538367A (ja) * 2005-04-18 2008-10-23 ブラッコ・リサーチ・ソシエテ・アノニム 超音波媒介デリバリー用ガス充填マイクロカプセル含有医薬組成物
DE102006026589A1 (de) * 2006-06-01 2007-12-06 Ossacur Ag Verwendung eines Kollagens mit osteoinduktiven Wirkstoffen zur Behandlung von Sehnen- und/oder Bänderdefekten
US8399619B2 (en) 2006-06-30 2013-03-19 Warsaw Orthopedic, Inc. Injectable collagen material
US8118779B2 (en) 2006-06-30 2012-02-21 Warsaw Orthopedic, Inc. Collagen delivery device
US9034002B2 (en) 2008-02-18 2015-05-19 Covidien Lp Lock bar spring and clip for implant deployment device
US9833240B2 (en) 2008-02-18 2017-12-05 Covidien Lp Lock bar spring and clip for implant deployment device
US10182898B2 (en) 2008-02-18 2019-01-22 Covidien Lp Clip for implant deployment device
US8758373B2 (en) 2008-02-18 2014-06-24 Covidien Lp Means and method for reversibly connecting a patch to a patch deployment device
US8808314B2 (en) 2008-02-18 2014-08-19 Covidien Lp Device and method for deploying and attaching an implant to a biological tissue
US10159554B2 (en) 2008-02-18 2018-12-25 Covidien Lp Clip for implant deployment device
US9044235B2 (en) 2008-02-18 2015-06-02 Covidien Lp Magnetic clip for implant deployment device
US8317808B2 (en) 2008-02-18 2012-11-27 Covidien Lp Device and method for rolling and inserting a prosthetic patch into a body cavity
US9398944B2 (en) 2008-02-18 2016-07-26 Covidien Lp Lock bar spring and clip for implant deployment device
WO2010029352A1 (en) * 2008-09-09 2010-03-18 University Of East Anglia Treatment of fibrotic eye disorders using an mmp2 inhibitor
US8888811B2 (en) 2008-10-20 2014-11-18 Covidien Lp Device and method for attaching an implant to biological tissue
US9999424B2 (en) 2009-08-17 2018-06-19 Covidien Lp Means and method for reversibly connecting an implant to a deployment device
US8906045B2 (en) 2009-08-17 2014-12-09 Covidien Lp Articulating patch deployment device and method of use
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US11912998B2 (en) 2010-01-28 2024-02-27 The Board Of Trustees Of The Leland Stanford Junior University Method of treating aging-associated cognitive impairment by reducing CCR3
US11236340B2 (en) 2010-01-28 2022-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of reducing the effects of aging-associated impairment of neurogenesis comprising modulating c-c chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
WO2012094708A1 (en) * 2011-01-12 2012-07-19 The University Of Queensland Bone graft biomaterial
US10688154B2 (en) 2011-04-08 2020-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
US9999408B2 (en) 2011-09-14 2018-06-19 Ethicon Endo-Surgery, Inc. Surgical instrument with fluid fillable buttress
US9089326B2 (en) 2011-10-07 2015-07-28 Ethicon Endo-Surgery, Inc. Dual staple cartridge for surgical stapler
EP2797953B1 (en) * 2011-12-28 2020-06-03 Amgen Inc. Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
US10688130B2 (en) 2013-12-09 2020-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
US10617744B2 (en) 2015-06-15 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions
US11141469B2 (en) 2015-06-15 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated conditions

Also Published As

Publication number Publication date
KR20050086949A (ko) 2005-08-30
EP1585555A2 (en) 2005-10-19
CA2509060A1 (en) 2004-07-22
WO2004060425A3 (en) 2005-01-06
AU2003300379A1 (en) 2004-07-29
US20040192658A1 (en) 2004-09-30
BR0317715A (pt) 2005-11-22
CN1732023A (zh) 2006-02-08
JP2006516252A (ja) 2006-06-29

Similar Documents

Publication Publication Date Title
US20040192658A1 (en) Compositions and methods of using collajolie
AU2002350361B2 (en) Compositions comprising collagen and metalloprotease inhibitors
CA2111193C (en) Tissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US8668703B2 (en) Medical devices incorporating collagen inhibitors
US10799622B2 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
CA2577022A1 (en) Compositions and methods using hyaluronic acid and hyluronidase inhibitors
JP6518198B2 (ja) 薬物放出のための化合物及び組成物
US6710025B1 (en) Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
JP2001131086A (ja) エンドセリンを含む結合組織修復促進組成物および該組成物の調製におけるエンドセリンの使用
AU2008202089A1 (en) Compositions comprising collagen and metalloprotease inhibitors
US20100105628A1 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
AU2016266102B2 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
AU2013204912B2 (en) Reducing post-operative adhesion formation with intraperitoneal glutamine
WO2017218432A1 (en) Fibrotic tissue stabilized by crosslinking for treatment of snoring and obstructive sleep apnea

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2509060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 169075

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1172/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004565732

Country of ref document: JP

Ref document number: 1020057012146

Country of ref document: KR

Ref document number: 20038A7727X

Country of ref document: CN

Ref document number: 2003814968

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2003300379

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 541397

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020057012146

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003814968

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0317715

Country of ref document: BR